no	Field Name	Datasource	Version	Title	do import	Link	is_list	Description	value_example (separated by ';')
1	chrom	ENSEMBLgene	v99	Chromosome	Y		N	name of the chromosome or scaffold; chromosome names without a 'chr'	1; 2; 3; 4; 5; 6; 7; X; 8; 9
2	spos	ENSEMBLgene	v99	Start position	Y		N	start position	11869; 14404; 17369; 29554; 30366; 34554; 52473; 57598; 65419; 89295
3	epos	ENSEMBLgene	v99	End position	Y		N	end position	14409; 29570; 17436; 31109; 30503; 36081; 53312; 64116; 71585; 133723
4	ensgid	ENSEMBLgene	v99	ENSEMBL gene ID	Y	https://useast.ensembl.org/Homo_sapiens/Gene/Summary?g=<ID>	N	The stable identifier for the gene	ENSG00000223972; ENSG00000227232; ENSG00000278267; ENSG00000243485; ENSG00000284332; ENSG00000237613; ENSG00000268020; ENSG00000240361; ENSG00000186092; ENSG00000238009
5	gene_version	ENSEMBLgene	v99	ENSEMBL gene version	Y		N	The stable identifier version for the gene	5; 1; 2; 3; 6; 7; 4; 10; 12; 11
6	gene_symbol	ENSEMBLgene	v99	Gene symbol	Y		N	The official symbol of this gene	DDX11L1; WASH7P; MIR6859-1; MIR1302-2HG; MIR1302-2; FAM138A; OR4G4P; OR4G11P; OR4F5; AL627309.1
7	gene_biotype	ENSEMBLgene	v99	Gene biotype	Y		N	The biotype of this gene	transcribed_unprocessed_pseudogene; unprocessed_pseudogene; miRNA; lncRNA; protein_coding; processed_pseudogene; snRNA; transcribed_processed_pseudogene; misc_RNA; TEC
8	cytoband	CYTOBAND	2017-07-17	Cytoband	Y		N	cytoband	1p36.33; 1p36.32; 1p36.31; 1p36.23; 1p36.22; 1p36.21; 1p36.13; 1p36.12; 1p36.11; 1p35.3
9	gene_summary	RefSeq	2020-03-20	Gene summary	Y		N	Gene summary from RefSeq	The protein encoded by this gene is expressed in neurons of most regions of the brain. It contains an N-terminal BTB domain, which mediates dimerization of the protein, and a C-terminal Kelch domain, which mediates binding to F-actin. This protein may play a key role in the regulation of actin-based neuronal function. [provided by RefSeq, Aug 2010].; The protein encoded by this gene is a ubiquitin-like protein that is conjugated to intracellular target proteins upon activation by interferon-alpha and interferon-beta. Several functions have been ascribed to the encoded protein, including chemotactic activity towards neutrophils, direction of ligated target proteins to intermediate filaments, cell-to-cell signaling, and antiviral activity during viral infections. While conjugates of this protein have been found to be noncovalently attached to intermediate filaments, this protein is sometimes secreted. [provided by RefSeq, Dec 2012].; This gene encodes one of several proteins that are critical in the development of the neuromuscular junction (NMJ), as identified in mouse knock-out studies. The encoded protein contains several laminin G, Kazal type serine protease inhibitor, and epidermal growth factor domains. Additional post-translational modifications occur to add glycosaminoglycans and disulfide bonds. In one family with congenital myasthenic syndrome affecting limb-girdle muscles, a mutation in this gene was found. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2015].; The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that this receptor promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. The knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell proliferation and differentiation. [provided by RefSeq, Jul 2008].; This gene encodes a stromal cell derived factor that is a member of the CREC protein family. The encoded protein contains six EF-hand motifs and calcium-binding motifs. This protein localizes to the Golgi lumen and may be involved in regulating calcium dependent cellular activities. [provided by RefSeq, Sep 2011].; DVL1, the human homolog of the Drosophila dishevelled gene (dsh) encodes a cytoplasmic phosphoprotein that regulates cell proliferation, acting as a transducer molecule for developmental processes, including segmentation and neuroblast specification. DVL1 is a candidate gene for neuroblastomatous transformation. The Schwartz-Jampel syndrome and Charcot-Marie-Tooth disease type 2A have been mapped to the same region as DVL1. The phenotypes of these diseases may be consistent with defects which might be expected from aberrant expression of a DVL gene during development. [provided by RefSeq, Jul 2008].; The protein encoded by this gene belongs to the cyclin family. Through its interaction with several proteins, such as RNA polymerase II, splicing factors, and cyclin-dependent kinases, this protein functions as a regulator of the pre-mRNA splicing process, as well as in inducing apoptosis by modulating the expression of apoptotic and antiapoptotic proteins. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2011]. COMPLETENESS: complete on the 3' end.; This gene encodes a transmembrane-domain containing protein found in the brain and cerebellum. Mutations in this gene result in spinocerebellar ataxia 21. [provided by RefSeq, Dec 2014].; The protein encoded by this gene is an E3 ubiquitin protein ligase that mediates ubiquitination of proteins in the Notch signaling pathway. The encoded protein may be a suppressor of melanoma invasion. [provided by RefSeq, Mar 2017].; This gene encodes a member of the serine/threonine protein kinase family. Members of this kinase family are known to be essential for eukaryotic cell cycle control. Due to a segmental duplication, this gene shares very high sequence identity with a neighboring gene. These two genes are frequently deleted or altered in neuroblastoma. The protein kinase encoded by this gene can be cleaved by caspases and may play a role in cell apoptosis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015].
10	hgnc_id	HGNC	2020-02-24	HGNC ID	Y	https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:<ID>	N	A unique ID provided by the HGNC for each gene with an approved symbol.	38034; 50039; 52482; 35294; 32334; 14822; 31276; 14825; 48835; 48063
11	name	HGNC	2020-02-24	Gene full name	Y		N	The full gene name approved by the HGNC.	WASP family homolog 7, pseudogene; microRNA 6859-1; MIR1302-2 host gene; microRNA 1302-2; family with sequence similarity 138 member A; olfactory receptor family 4 subfamily G member 4 pseudogene; olfactory receptor family 4 subfamily G member 11 pseudogene; olfactory receptor family 4 subfamily F member 5; capicua transcriptional repressor pseudogene 27; RNA, U6 small nuclear 1100, pseudogene
12	locus_group	HGNC	2020-02-24	Locus group	Y		N		pseudogene; non-coding RNA; protein-coding gene; other
13	locus_type	HGNC	2020-02-24	Locus type	Y		N	Specifies the genetic class of each gene entry.	pseudogene; RNA, micro; RNA, long non-coding; gene with protein product; readthrough; RNA, small nuclear; RNA, small nucleolar; unknown; RNA, ribosomal; immunoglobulin gene
14	alias_symbol	HGNC	2020-02-24	Alias gene symbol	Y		Y	Alias gene symbol	FAM39F; hsa-mir-6859-1; hsa-mir-1302-2; F379; hsa-mir-6859-2; FLJ40008; FLJ22639; AL645608.1; MGC45873; DKFZP434H2010
15	alias_name	HGNC	2020-02-24	Alias gene name	Y		Y	Alias gene name	family with sequence similarity 39, member F; actinfilin; calcium binding protein; limitrin; GABA(A) receptor, delta; p53-dependent apoptosis modulator; NSUN2 methylated lncRNA; cellubrevin; intestinal facilitative glucose transporter 7; cellular retinol binding protein 7
16	prev_symbol	HGNC	2020-02-24	Previous gene symbol	Y		Y	This field displays any symbols that were previously HGNC-approved nomenclature.	MIRN1302-2; NCRNA00115; AGRIN; MIRN200B; MIRN200A; MIRN429; CENTB5; GLTPD1; C1orf233; MIRN551A
17	prev_name	HGNC	2020-02-24	Previous gene name	Y		Y	This field displays any names that were previously HGNC-approved nomenclature.	WAS protein family homolog 7, pseudogene; family with sequence similarity 138, member A; olfactory receptor, family 4, subfamily G, member 4 pseudogene; olfactory receptor, family 4, subfamily G, member 11 pseudogene; olfactory receptor, family 4, subfamily F, member 5; WW domain binding protein 1-like pseudogene 7; olfactory receptor, family 4, subfamily F, member 29; capicua homolog (Drosophila) pseudogene 7; mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 pseudogene 23; mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 pseudogene 28
18	entrez_id	HGNC	2020-02-24	NCBI Gene	Y	https://www.ncbi.nlm.nih.gov/gene/<ID>	N	NCBI Gene ID	653635; 102466751; 107985730; 100302278; 645520; 79504; 403263; 79501; 100420257; 106480049
19	vega_id	HGNC	2020-02-24	VEGA	N	http://vega.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=<ID>	N		OTTHUMG00000000958; OTTHUMG00000000959; OTTHUMG00000000960; OTTHUMG00000185779; OTTHUMG00000001095; OTTHUMG00000001094; OTTHUMG00000001257; OTTHUMG00000191963; OTTHUMG00000002854; OTTHUMG00000002859
20	ucsc_id	HGNC	2020-02-24	UCSC	Y		N	UCSC genome browser gene ID	uc031tlb.1; uc001aak.4; uc001aal.1; uc010nxu.2; uc010nxv.2; uc031tlt.2; uc010nxx.3; uc001abt.5; uc001abw.2; uc001aca.3
21	refseq_accession	HGNC	2020-02-24	RefSeq	Y	https://www.ncbi.nlm.nih.gov/gene/?term=<ID>	Y	The Reference Sequence (RefSeq) collection	NR_024540; NR_106918; XR_001737835; NR_036051; NR_026818; NG_004148; NG_004423; NM_001005484; NG_027060; NG_045795
22	ccds_id	HGNC	2020-02-24	CCDS	Y	https://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi?REQUEST=CCDS&DATA=<ID>	Y	The Consensus CDS (CCDS) project: a collaborative effort to identify a core set of human and mouse protein coding regions that are consistently annotated and of high quality	CCDS30547; CCDS72675; CCDS41221; CCDS2; CCDS30550; CCDS4; CCDS5; CCDS30551; CCDS53257; CCDS7
23	uniprot_ids	HGNC	2020-02-24	UniProt	Y	https://www.uniprot.org/uniprot/<ID>	Y	UniProt accession number	Q8NH21; Q6IEY1; Q96NU1; Q6TDP4; CCDS53256; CCDS44034; O00468; E7ERA6; CCDS81250; CCDS30553
24	pubmed_id	HGNC	2020-02-24	PubMed	Y	https://pubmed.ncbi.nlm.nih.gov/<ID>	Y	PubMed	18159949; 11779631; 19123937; 14983052; 12477932; 29707762; 27734943; 12063253; Q494U1; Q9HCC6
25	mgd_id	HGNC	2020-02-24	MGI	N	http://www.informatics.jax.org/marker/<ID>	Y	Mouse Genome Informatics Database	15233989; MGI:3031137; MGI:2446220; MGI:2678948; 11230166; 11260262; 12270958; MGI:3588193; Q96HA4; MGI:2676875
26	rgd_id	HGNC	2020-02-24	MouseMine	N	http://ratmine.mcw.edu/ratmine/portal.do?externalids=<ID>&class=Gene&origin=MouseMine	Y		RGD:1566059; RGD:1334011; RGD:1310271; RGD:708444; MGI:2387630; 15254753; MGI:87961; RGD:1587009; 12975309; RGD:2325552
27	lsdb	HGNC	2020-02-24	LRG	N		Y	A Locus Reference Genomic (LRG) record contains stable reference sequences that are used for reporting sequence variants with clinical implications	RGD:1311019; RGD:2067; MGI:2444364; MGI:108079; RGD:1310711; 14603461; MGI:2685285; MGI:1919214; MGI:2183149; RGD:61901
28	cosmic	HGNC	2020-02-24	Cosmic	Y	https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=<ID>	N	Catalog of somatic mutations in cancer	OR4F5; OR4F29; OR4F16; FAM87B; SAMD11; KLHL17; Leiden Muscular Dystrophy pages; RNF223; RGD:1311517; RGD:621521
29	omim_id	HGNC	2020-02-24	OMIM	Y	https://omim.org/entry/<ID>	Y	Online Mendelian Inheritance in Man (OMIM)	616765; PLEKHN1; http://www.dmd.nl/nmdb2/home.php?select_db=AGRN; 612091; 612090; 612094; ACAP3; 615467; 605865; RGD:1359356
30	mirbase	HGNC	2020-02-24	miRBase	N	http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=<ID>	N	the microRNA database	MI0022705; MI0006363; MI0026420; HES4; LRG_198; C1orf159; MI0000342; MI0000737; MI0001641; SDF4
31	homeodb	HGNC	2020-02-24	HomeoDB	N	http://homeodb.zoo.ox.ac.uk/gene_info.get?id=<ID>&og=Human	N	a database of homeobox gene diversity	608060; http://ftp.ebi.ac.uk/pub/databases/lrgex/LRG_198.xml; 614282; MXRA8; 612316; 611616; 176982; 602859; O15350; 606351
32	snornabase	HGNC	2020-02-24	snoRNABase	N	https://www-snorna.biotoul.fr/plus.php?id=<ID>	N	database of human H/ACA and C/D box snoRNAs	AGRN; 617293; 9296498; 615242; 611501; RGD:1309588; AGTRAP; 611624; 167410; 603929
33	orphanet	HGNC	2020-02-24	OrphaNet	Y	https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=<ID>	N	portal for rare diseases and orphan drugs	311140; MGI:1336991; SLC2A5; 470868; UBIAD1; 470258; 209474; 477544; 8485; 600423
34	enzyme_id	HGNC	2020-02-24	ENZYME	Y	http://enzyme.expasy.org/EC/<ID>	Y	ENZYME database	1.1.1.43; 2.5.1.16; 2.7.10.1; 3.5.3.15; 3.1.1.4; objectId:1615; 3.1.1.5; objectId:3041; 2.7.7.30; CD106
35	ClinGen	ClinGen	20200309	ClinGen	Y	https://search.clinicalgenome.org/kb/genes/HGNC:<ID>	N	ClinGen	329; 17978; 4396; 10896; 12003; 19104; 13281; 29105; 18806; 16369
36	clinical_validity	ClinGen	20200309	Clinical Validity	N		N		Curated
37	evidence	ClinGen	20200309	Evidence-Based Summary	N		N		Curated
38	haploinsufficiency_score	ClinGen	20200309	Haploinsufficiency Score	N		N		Associated with Autosomal Recessive Phenotype; Minimal Evidence; No Evidence; Sufficient Evidence; Dosage Sensitivity Unlikely; Some Evidence
39	triplosensitivity_score	ClinGen	20200309	Triplosensitivity Score	N		N		No Evidence; Minimal Evidence; Sufficient Evidence; Dosage Sensitivity Unlikely; Moderate Evidence
40	disease_label	ClinGenDisease	20200309	Disease Label	Y		Y	Disease label list	Shprintzen-Goldberg syndrome; homocystinuria due to methylene tetrahydrofolate reductase deficiency; hyperprolinemia type 2; C1Q deficiency; 3-hydroxy-3-methylglutaric aciduria; hypertrophic cardiomyopathy; Stickler syndrome; nonsyndromic genetic deafness; GLUT1 deficiency syndrome; nevoid basal cell carcinoma syndrome
41	disease_id	ClinGenDisease	20200309	Disease ID (MONDO)	Y	https://search.clinicalgenome.org/kb/conditions/<ID>	Y		MONDO_0008426; MONDO_0009353; MONDO_0009401; MONDO_0013343; MONDO_0009520; MONDO_0005045; MONDO_0019354; MONDO_0019497; MONDO_0000188; MONDO_0007187
42	Inheritance	ClinGenDisease	20200309	Inheritance	Y		Y		Autosomal Dominant; Autosomal Recessive; Semidominant; X-Linked; X-linked recessive; Other
43	classification	ClinGenDisease	20200309	Classification	Y		Y		Definitive; Moderate; Limited; Strong; Disputed; No Reported Evidence; Refuted
44	online_report	ClinGenDisease	20200309	Online report	Y		Y		https://search.clinicalgenome.org/kb/gene-validity/4841; https://search.clinicalgenome.org/kb/gene-validity/cbfc5297-ed0d-4d7c-bca6-747114ed2b17--2019-06-18T16:00:00; https://search.clinicalgenome.org/kb/gene-validity/5edc3f72-31e0-47f8-bcec-e3e5b81c97ae--2019-09-13T17:27:15; https://search.clinicalgenome.org/kb/gene-validity/3216; https://search.clinicalgenome.org/kb/gene-validity/f4d084e5-a740-4bfd-a850-d6db900d4a4e--2018-06-26T16:00:00; https://search.clinicalgenome.org/kb/gene-validity/d9f35d3c-2d30-4947-9d10-87d21405586e--2018-08-01T16:33:16; https://search.clinicalgenome.org/kb/gene-validity/697ae26e-2b07-4f87-b42c-121684c89bc0--2019-02-19T17:00:00; https://search.clinicalgenome.org/kb/gene-validity/88196c6d-4bd7-4aff-ba98-c7b4411c562d--2017-11-21T17:00:00; https://search.clinicalgenome.org/kb/gene-validity/a20a0bc0-49d5-41fc-9507-cec19a43bd81--2019-04-18T12:34:54; https://search.clinicalgenome.org/kb/gene-validity/d189ca00-ba80-49af-9b2e-8523c8d29a44--2018-10-12T21:39:08
45	classification_date	ClinGenDisease	20200309	Classification date	Y		Y		2016-12-01 00:00:00; 2019-06-18 16:00:00.000; 2019-09-13 17:27:15.767; 2017-01-09 00:00:00; 2018-06-26 16:00:00.000; 2018-08-01 16:33:16.590; 2019-02-19 17:00:00.000; 2017-11-21 17:00:00.000; 2019-04-18 12:34:54.696; 2018-10-12 21:39:08.660
46	Ensembl_TRS	ENSEMBLIDxref	v2.1.1	ENSEMBL transcript	Y	https://useast.ensembl.org/Homo_sapiens/Transcript/Summary?t=<ID>	Y	ENSEMBL transcript ID list	ENST00000641515; ENST00000426406; ENST00000332831; ENST00000420190; ENST00000327044; ENST00000338591; ENST00000379410; ENST00000341290; ENST00000428771; ENST00000624697
47	Ensembl_PRO	ENSEMBLIDxref	v2.1.1	ENSEMBL protein	Y	http://www.ensembl.org/Homo_sapiens/protview?peptide=<ID>	Y	ENSEMBL protein ID list	ENST00000335137; ENST00000426406; ENST00000332831; ENST00000437963; ENSP00000317992; ENST00000466300; ENST00000379409; ENST00000433179; ENST00000304952; ENST00000624652
48	UniRef100	ENSEMBLIDxref	v2.1.1	UinRef 100% sequence identity genes	Y	https://www.uniprot.org/uniref/<ID>	Y	UniRef100 combines identical sequences and sub-fragments with 11 or more residues from any organism into a single UniRef entry.	A0A4Y7LJF4_HUMAN; OR4E2_HUMAN; ENST00000622503; 229463046; Q6TDP4; ENSP00000368717; PERL_HUMAN; E9PB28; A0A096LPJ4; ENSP00000499046
49	UniRef90	ENSEMBLIDxref	v2.1.1	UinRef 90% sequence identity genes	Y	https://www.uniprot.org/uniref/<ID>	Y	UniRef90 is built by clustering UniRef100 sequences such that each cluster is composed of sequences that have at least 90% sequence identity to, and 80% overlap with, the longest sequence (a.k.a. seed sequence).	A0A2U3U0J3_HUMAN; OR4F3_HUMAN; ENST00000618323; 1034654098; J3QLT4; ENSP00000462558; PERM1_HUMAN; Q9HCC6; A0A096LNZ9; ENSP00000484607
50	UniRef50	ENSEMBLIDxref	v2.1.1	UinRef 50% sequence identity genes	Y	https://www.uniprot.org/uniref/<ID>	Y	UniRef50 is built by clustering UniRef90 seed sequences that have at least 50% sequence identity to, and 80% overlap with, the longest sequence in the cluster.	OR4F4_HUMAN; A0A0S2Z5W7_HUMAN; ENST00000616016; 333470751; Q0VGE6; Q494U1; LPO; D6REB3; P05161; O00468
51	UniParc	ENSEMBLIDxref	v2.1.1	UniParc	Y	https://www.uniprot.org/uniparc/<ID>	Y	The UniProt Archive (UniParc) is a comprehensive and non-redundant database that contains most of the publicly available protein sequences in the world.	OR4F5_HUMAN; A0A126GV92_HUMAN; ENST00000618779; 3041859; KLH15_HUMAN; Q494U1; 1209685; E9LY07_HUMAN; A0A096LNQ0_HUMAN; A0A494C0G5
52	NCBInucleotide	ENSEMBLIDxref	v2.1.1	NCBI Nucleotide	Y	https://www.ncbi.nlm.nih.gov/nuccore/<ID>	Y		HLA-C; OR4E2; ENST00000616125; 23503106; KLH17_HUMAN; Q494U1; 231569458; E9PB28_HUMAN; A0A096LPJ4_HUMAN; A0A494C1I6
53	NCBIprotein	ENSEMBLIDxref	v2.1.1	NCBI Protein	Y	https://www.ncbi.nlm.nih.gov/protein/<ID>	Y		OR4F4; ACBD4; ENST00000620200; 13097693; B4DWR6_HUMAN; J3KSM5; 119614880; HES3_HUMAN; Q67AQ5_HUMAN; A0A087X208
54	PDB	ENSEMBLIDxref	v2.1.1	PDB	Y	https://www.rcsb.org/structure/<ID>	Y	The Protein Data Bank (PDB) [1] is a database for the three-dimensional structural data of large biological molecules, such as proteins and nucleic acids.	38372849; 1034562110; ENSP00000349216; UniRef100_Q9Y3T9; AGER; PLEKHM3; 32187529; HES3; HLA-DPB1; A0A484HK63_HUMAN
55	BioGrid	ENSEMBLIDxref	v2.1.1	BioGrid	Y	https://thebiogrid.org/<ID>	Y	BioGRID is an interaction repository with data compiled through comprehensive curation efforts.	29537517; 119943152; ENSP00000412228; UniRef90_O60393; 578837965; MED24; 187224; RANBP3L; ISCU; A0A494C1I6_HUMAN
56	DIP	ENSEMBLIDxref	v2.1.1	DIP	Y	https://dip.doe-mbi.ucla.edu/dip/DIPview.cgi?PK=<ID>	N	Database of Interacting Proteins	28798607; 52421349; ESP00000480870; UniRef90_Q9Y3T9; 226442729; 122937347; 12643419; 320332336; 758099; A0A087WY58_HUMA
57	MINT	ENSEMBLIDxref	v2.1.1	MINT	Y	https://mint.bio.uniroma2.it/index.php/results-interactions/?id=<ID>	Y	The Molecular INTeraction Database	38372801; 1034562112; ENSP00000482138; UniRef50_O60393; 16552933; 223462685; 586830542; 216548627; 37021637; A0A087X208_HUMAN
58	STRING	ENSEMBLIDxref	v2.1.1	STRING	Y	https://string-db.org/network/<ID>	Y	STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) is a biological database and web resource of known and predicted proteinâ€“protein interactions.	21928461; 1034562116; ENSP00000480678; UniRef50_Q9Y3T9; 12697899; 34528693; 1034562655; 66912172; 1685102; ADGRG7
59	ChEMBL	ENSEMBLIDxref	v2.1.1	ChEMBL	Y	https://www.ebi.ac.uk/chembl/target_report_card/<ID>/	Y	Manually curated database of bioactive molecules with drug-like properties.	53828740; 1034644538; ENSP00000478421; UPI00019B220C; 21739921; 18088745; 34529498; 74746514; 313104118; WAC
60	DrugBank	ENSEMBLIDxref	v2.1.1	DrugBank	Y	https://www.drugbank.ca/drugs/<ID>	Y	The DrugBank database is a bioinformatics and cheminformatics resource that combines detailed drug data with comprehensive drug target information.	UniRef100_A0A4Y7LJF4; 74762307; ENSP00000484256; UPI00019B220B; 88909167; 172046173; 1034562657; 15214449; 15080288; RHD
61	BioMuta	ENSEMBLIDxref	v2.1.1	BioMuta	N		Y	A single-nucleotide variation (SNV) and disease association database where variations are mapped to genomes and RefSeq nucleotide entries, and unified through UniProtKB/Swiss-Prot positional coordinates.	UniRef100_Q8NH21; 1034562114; ENSP00000484643; UPI000041820C; 15929973; 767918095; 607344299; 10121150; 987996593; NEK3
62	DMDM	ENSEMBLIDxref	v2.1.1	DMDM	N		Y		UniRef100_Q96R69; 52627209; ENSP00000484820; AC004534; 38194229; 160419245; 607344301; 119576700; 38303902; 28195603
63	CPTAC	ENSEMBLIDxref	v2.1.1	CPTAC	N		Y		UniRef90_P30686; 957951562; ENSP00000482090; AL050019; 37791471; 71682157; 158563938; 10863967; 11545707; 109731698
64	ProteomicsDB	ENSEMBLIDxref	v2.1.1	ProteomicsDB	N		Y		UniRef90_Q8NGA8; 578831409; A6PWC8; AL645608; 52783052; 237820624; 523545115; 34098717; 24307953; 14041985
65	DNASU	ENSEMBLIDxref	v2.1.1	DNASU	N		Y		UniRef50_P17693; 187950697; Q5SV95; BC003555; 194377134; 119576703; UniRef100_P22079; 311643801; 56699456; 238859647
66	GeneID	ENSEMBLIDxref	v2.1.1	NCBI gene	N		Y		UPI0000041E1E; UniRef100_A0A0S2Z5W7; A0A087WXB3; 9606; UniRef100_Q6TDP4; 237820622; UniRef50_P22079; UniRef100_Q5TGS1; 67463938; 1947080
67	KEGG	ENSEMBLIDxref	v2.1.1	KEGG	Y	https://www.genome.jp/dbget-bin/www_bget?<ID>	Y		UPI0000041BC1; UniRef90_Q8NGC2; A0A087WYW1; CCDS47736.2; UniRef100_B4DWR6; UniRef100_Q6ZWE6; UniRef50_Q5SV97; UniRef100_Q9HCC6; 340780633; 530360311
68	EuPathDB	ENSEMBLIDxref	v2.1.1	EuPathDB	N	https://www.eupathdb.org/gene/<ID>	Y		LT989888; UniRef90_Q6IEY1; A0A087WX24; NP_001073882.3; UniRef100_J3QLT4; UniRef100_Q494U1; UPI0000131631; UniRef100_D6RCM9; 335892445; 2988422
69	GeneCards	ENSEMBLIDxref	v2.1.1	GeneCards	Y	https://www.genecards.org/cgi-bin/carddisp.pl?gene=<ID>	Y	a database of human genes that provides genomic, proteomic, transcriptomic, genetic and functional information on all known and predicted human genes.	AL627309; UniRef90_A0A2K5VRT4; I7G285; XP_016867231.1; UniRef100_A0A0G2JL37; UniRef100_J3KSL1; UPI0001A4717E; UniRef100_D6REB3; 30583433; 54873613
70	HPA	ENSEMBLIDxref	v2.1.1	Human Protein Atlas	Y	https://www.proteinatlas.org/search/<ID>	Y	Human Protein Atlas	BC136907; UniRef50_Q6IEY1; A0A087X223; NM_001080413.3; UniRef90_Q96M94; UniRef90_Q8BM47; U39573; UniRef90_A0A2K5RL97; 52001470; 14043307
71	neXtProt	ENSEMBLIDxref	v2.1.1	neXtProt	Y	https://www.nextprot.org/entry/<ID>/	Y		AF399574; UPI0000041D88; A0A087WYU3; UniRef90_B4DWR6; UniRef90_J3KSL1; AY324876; UniRef90_Q9HCC6; 339961370; 114152771; XM_011523980.2
72	PharmGKB	ENSEMBLIDxref	v2.1.1	PharmGKB	Y	https://www.pharmgkb.org/gene/<ID>	Y	a publicly available, online knowledgebase responsible for the aggregation, curation, integration and dissemination of knowledge regarding the impact of human genetic variation on drug response.	BK004223; UPI0000041D3C; X5D9M6_HUMAN; UniRef90_J3QLT4; UniRef90_Q494U1-2; AC004687; UniRef90_Q86VV4; 335892446; 39795260; XM_011523981.2
73	eggNOG	ENSEMBLIDxref	v2.1.1	eggNOG	Y	http://eggnogdb.embl.de/#/app/results#<ID>	Y	It is based on the original idea of COGs and expands that idea to non-supervised orthologous groups constructed from numerous organisms.	AB065592; UPI000387CF9A; A6PWC8_HUMAN; UniRef90_Q15109-6; UniRef50_Q8BM47; AC005962; UniRef50_A0A2K5LIZ5; 319443765; 765826147; J3QRL0
74	GeneTree	ENSEMBLIDxref	v2.1.1	GeneTree	N		Y		SPI37852.1; AB065895; M9P977_HUMAN; UniRef90_F7ANQ0; UniRef50_Q494U1; BC107166; UniRef50_Q9HCC6; 4826774; 21706410; 569148
75	HOGENOM	ENSEMBLIDxref	v2.1.1	HOGENOM	N		Y	Database of Complete Genome Homologous Genes Families	AAI36908.1; AF399581; Q5SV95_HUMAN; 9606.ENSP00000419457; UniRef50_Q96M94; UniRef50_J3KSL1; BC107167; UniRef50_Q5TGS1; 27362957; 1476413402
76	KO	ENSEMBLIDxref	v2.1.1	KEGG Ontology	Y	https://www.genome.jp/dbget-bin/www_bget?ko:<ID>	Y	KEGG Ontology	AAI36909.1; BK004526; SAM10_HUMAN; UniRef50_Q6TDP4; UPI000166304A; M58151; UniRef50_Q6PDH4; 386837; 38196963; B2REC5
77	OMA	ENSEMBLIDxref	v2.1.1	OMA	N		Y		AAK95059.1; AL732372; SAM11_HUMAN; UniRef50_B4DWR6; UPI0000DBEE58; KF150175; UPI0001CF2A0F; 112491366; 53791229; 9606.ENSP00000382330
78	OrthoDB	ENSEMBLIDxref	v2.1.1	OrthoDB	Y	https://www.orthodb.org/?query=<ID>	Y	OrthoDB presents a catalog of orthologous protein-coding genes across vertebrates, arthropods, fungi, plants, and bacteria.	DAA04621.1; BC137547; C9JZE8_HUMAN; NOBOX; UniRef50_J3QLT4; UPI00002377C5; AK123855; UPI0001881B51; 119576699; UniRef100_Q96K78
79	TreeFam	ENSEMBLIDxref	v2.1.1	TreeFam	N	http://www.treefam.org/family/<ID>	Y	Database of animal gene trees	BAC05820.1; BK004481; H7BY14_HUMAN; UniRef50_Q15109; UPI00001416D8; AL645608; UPI000047096C; UniRef100_B4E187; UniRef100_O00468; CA159_HUMAN
80	Reactome	ENSEMBLIDxref	v2.1.1	Reactome	Y	https://reactome.org/content/detail/<ID>	Y		9606; KU178780; F2WG57_HUMAN; UPI000019832F; UPI000268B00E; BC006300; UPI000006EC19; UniRef100_P05161; UniRef100_Q9BTA9; RNF222
81	ChiTaRS	ENSEMBLIDxref	v2.1.1	ChiTaRS	N		Y	Database of chimeric transcripts and RNA-seq data	CCDS32343.1; KP290153; H7C3J6_HUMAN; 49389; UPI00001DFBF0; UPI000268AE1F; AAC50717.1; UPI0001D3B176; UniRef100_S6B6Q1; UniRef100_A0A494C0G5
82	GeneWiki	ENSEMBLIDxref	v2.1.1	GeneWiki	N		Y		NP_001004195.2; BAC06111.1; A0A087WW16_HUMAN; 49390; UPI00017A8154; AC083900; ABQ53140.1; UPI0001D3BBEE; UniRef100_Q9H1K1; UniRef100_A0A484HK63
83	GenomeRNAi	ENSEMBLIDxref	v2.1.1	GenomeRNAi	N		Y		NP_001005484.1; AAK95066.1; A0A087WXB3_HUMAN; 135935; UPI000268AE1E; AC096772; AAP72968.1; HQ154163; UniRef90_B4E187; UniRef100_A0A494C1I6
84	CRC64	ENSEMBLIDxref	v2.1.1	CRC64	N		Y		NM_001004195.2; DAA04924.1; A0A087WYH2_HUMAN; ENSG00000106410; UPI000215117A; BC020812; AAI07167.1; AL645608; UniRef90_P05161; UniRef100_A0A087WY58
85	UniProt	ENSEMBLIDxref	v2.1.1	UniProt	Y	https://www.uniprot.org/uniprot/<ID>	Y	UniProt is a freely accessible database of protein sequence and functional information, many entries being derived from genome sequencing projects.	ENSP00000493376; ENSP00000409316; ENSP00000329982; ENST00000342066; Q9Y3T9; ENST00000622660; ENST00000379407; ENSP00000343864; ENST00000484667; ENST00000649529
86	GO	ENSEMBLIDxref	v2.1.1	Gene Ontology	Y	https://www.ebi.ac.uk/QuickGO/term/<ID>	Y	Gene Ontology	DAA04879.1; A0A087WV57_HUMAN; ENST00000467773; AK057298; AK123204; AAA63213.1; AB048791; UniRef90_Q9H1K1; UniRef90_O00468; ENSG00000237330
87	PIR	ENSEMBLIDxref	v2.1.1	PIR	N		Y		ALQ34238.1; A0A087WX24_HUMAN; ENST00000483238; BC015415; AL136730; AGQ48858.1; BC012351; UniRef50_B4E187; UniRef90_Q9BTA9; ENST00000344001
88	Gene_Synonym	ENSEMBLIDxref	v2.1.1	Gene_Synonym	N		Y		OR4F4; NP_001005224.1; A0A087X1H5_HUMAN; 135935; AY423763; AC090844; CCDS54149.1; BAB13510.1; UPI0004F23698; UniRef50_O00468
89	ComplexPortal	ENSEMBLIDxref	v2.1.1	ComplexPortal	Y	https://www.ebi.ac.uk/complexportal/complex/<ID>	Y	The Complex Portal is a manually curated, encyclopaedic resource of macromolecular complexes from a number of key model organisms.	38372849; NP_001005277.1; A0A087X223_HUMAN; 26155; AL645608; AC102799; NP_001153574.1; AAH12351.1; UPI0000089275; UniRef50_Q9BTA9
90	TCDB	ENSEMBLIDxref	v2.1.1	TCDB	N	http://www.tcdb.org/search/result.php?tc=<ID>	Y	Functional and Phylogenetic Classification of Membrane Transport Proteins	XP_016857897.1; A0A087X0Q0_HUMAN; hsa:135935; AK301650; AAH20812.1; NP_006142.1; 9606; UPI00053BD5BA; UniRef50_P18577; 401934
91	BioCyc	ENSEMBLIDxref	v2.1.1	BioCyc	Y	https://biocyc.org/getid?id=<ID>	N	BioCyc is a collection of 17043 Pathway/Genome Databases (PGDBs), plus software tools for exploring them.	77933; XP_016857898.1; A0A087X2A3_HUMAN; HostDB:ENSG00000106410.14; CR812478; AAI51138.1; NP_001278295.1; CCDS41238.1; UPI000021CA9A; UniRef50_P51956
92	GeneReviews	ENSEMBLIDxref	v2.1.1	GeneReviews	Y	https://www.ncbi.nlm.nih.gov/books/NBK1116/?term=<ID>%5BGeneSymbol%5D	Y	GeneReviews	XP_016857899.1; A0A087WWQ4_HUMAN; NOBOX; CR933878; BAC85557.1; NP_001278296.1; NP_001135939.1; UPI000007018B; UPI000004B6DF; HostDB:ENSG00000189051.5
93	SwissLipids	ENSEMBLIDxref	v2.1.1	SwissLipids	N		Y		ENSG00000186092; XP_016857900.1; A0A087WYU3_HUMAN; HGNC:22448; BC105742; CAB66664.1; XP_016858072.1; NP_001019769.1; UPI0000048D70; UPI000387D73E
94	UniPathway	ENSEMBLIDxref	v2.1.1	UniPathway	Y	https://www.nextprot.org/term/<ID>/	Y	UniPathway	ENSG00000177693; XP_016864827.1; CNTNAP2; CH471183; EAW56299.1; XP_016858073.1; NP_066993.1; AC007878; UPI001088D15F; HGNC:34517
95	Gene_ORFName	ENSEMBLIDxref	v2.1.1	Gene_ORFName	N		Y		ENSG00000288513; XP_006722148.1; HLA-A; 610934; BAB71415.1; AAI01387.1; NM_001160102.1; XP_005244828.1; AC096569; UPI0010872C9B
96	GlyConnect	ENSEMBLIDxref	v2.1.1	GlyConnect	N		Y		ENST00000641515; XM_006722085.2; SAMD10; 611548; AAH15415.1; AAI01388.1; NM_006151.2; NM_001024598.3; AC104084; UPI0010BB94D6
97	DisProt	ENSEMBLIDxref	v2.1.1	DisProt	N		Y		ENST00000326183; GPM6B; 610770; AAI09059.1; 9606; AC109343; UPI000387B6E0; NX_A6NCQ9; SEC24C; 545739602
98	GuidetoPHARMACOLOGY	ENSEMBLIDxref	v2.1.1	GuidetoPHARMACOLOGY	N		N		ENST00000673169; ATP6; NX_O60393; AAI09060.1; CCDS42808.1; 110207; AL645608; UPI0004620DA5; PA164725453; TTYH2
99	MEROPS	ENSEMBLIDxref	v2.1.1	MEROPS	N		Y		ENST00000335137; MED25; BAB21768.1; NP_001073944.1; AY375804; UPI0004E4CB7F; ENOG410J277; SLC38A11; 225698138; UPI0000035975
100	ESTHER	ENSEMBLIDxref	v2.1.1	ESTHER	N		Y		ENSP00000493376; PCDHGA3; KOG0490; CAD38983.1; XP_011509462.1; AY009127; AY181246; ENOG411286J; HLA-B; 544332701
101	Allergome	ENSEMBLIDxref	v2.1.1	Allergome	N		Y		ENSP00000317482; 9606.ENSP00000386195; ZMYND8; ENOG410YIJ3; AAR03710.1; NP_001153656.1; 9606.ENSP00000262290; 9606.ENSP00000367130; AY009128; AK027360
102	PeroxiBase	ENSEMBLIDxref	v2.1.1	PeroxiBase	N		Y		ENSP00000500162; ATPase 6; ENSGT00650000093445; BAG63128.1; NP_115505.2; CHEMBL5898; AC008119; CH471052; HOG000137599; PPP4R1
103	REBASE	ENSEMBLIDxref	v2.1.1	REBASE	N		Y		ENSP00000334393; SRGAP2B; HOG000113810; AAI05743.1; NM_001080475.2; BC011906; BC113451; PRR5; 482676907; Z29574
104	PATRIC	ENSEMBLIDxref	v2.1.1	PATRIC	N	https://www.patricbrc.org/search/?keyword("<ID>")	Y	PATRIC, the Pathosystems Resource Integration Center, provides integrated data and analysis tools to support biomedical research on bacterial infectious diseases.	26682; OR4E2; ACAP2; EAW56302.1; XM_011511160.2; LPO; HES3; BC061903; AB191264; TRSFCCR
105	Pathway(BioCarta)_short	dbNSFP	4.0c	BioCarta	Y	http://amp.pharm.mssm.edu/Harmonizome/search?t=geneSet&q=<ID>	N	Short name of the Pathway(s) the gene belongs to (from BioCarta)	ox40Pathway; PROSITE-ProRule:PRU00388}.; agrPathway;alkPathway;gsk3Pathway;pitx2Pathway;ps1Pathway;hesPathway;wntPathway; acrPathway; HivnefPathway; gsPathway;CSKPathway;sppaPathway;agpcrPathway;biopeptidesPathway;CCR3Pathway;gcrPathway;cxcr4Pathway;erkPathway;fMLPpathway;tubbyPathway;mPRPathway;raccPathway;edg1Pathway;myosinPathway;gpcrPathway;bArrestinPathway;Par1Pathway; ptdinsPathway; myosinPathway;Par1Pathway; atmPathway; DNAfragmentPathway;caspasePathway;fasPathway;setPathway;HivnefPathway;deathPathway;mitochondriaPathway;tnfr1Pathway
106	Pathway(BioCarta)_full	dbNSFP	4.0c	BioCarta pathway	Y		N	Full name(s) of the Pathway(s) the gene belongs to (from BioCarta)	OX40 Signaling Pathway; Agrin in Postsynaptic Differentiation;ALK in cardiac myocytes;Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages;Multi-step Regulation of Transcription by Pitx2;Presenilin action in Notch and Wnt signaling;Segmentation Clock;WNT Signaling Pathway; Ahr Signal Transduction Pathway; HIV-I Nef: negative effector of Fas and TNF; Activation of cAMP-dependent protein kinase, PKA;Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor;Aspirin Blocks Signaling Pathway Involved in Platelet Activation;Attenuation of GPCR Signaling;Bioactive Peptide Induced Signaling Pathway;CCR3 signaling in Eosinophils;Corticosteroids and cardioprotection;CXCR4 Signaling Pathway;Erk1/Erk2 Mapk Signaling pathway;fMLP induced chemokine gene expression in HMC-1 cells;G-Protein Signaling Through Tubby Proteins;How Progesterone Initiates Oocyte Membrane;Ion Channels and Their Functional Role in Vascular Endothelium;Phospholipids as signalling intermediaries;PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase;Signaling Pathway from G-Protein Families;b-arrestins in GPCR Desensitization;Thrombin signaling and protease-activated receptors; Phosphoinositides and their downstream targets.; PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase;Thrombin signaling and protease-activated receptors; ATM Signaling Pathway; Apoptotic DNA fragmentation and tissue homeostasis;Caspase Cascade in Apoptosis;FAS signaling pathway ( CD95 );Granzyme A mediated Apoptosis Pathway;HIV-I Nef: negative effector of Fas and TNF;Induction of apoptosis through DR3 and DR4/5 Death Receptors ;Role of Mitochondria in Apoptotic Signaling;TNFR1 Signaling Pathway; Induction of apoptosis through DR3 and DR4/5 Death Receptors
107	Pathway(ConsensusPathDB)	dbNSFP	4.0c	Pathway(ConsensusPathDB)	Y		N	Pathway(s) the gene belongs to (from ConsensusPathDB)	Olfactory transduction - Homo sapiens (human);Olfactory receptor activity;Signaling by GPCR;Signal Transduction;Olfactory Signaling Pathway;G alpha (s) signalling events;GPCR downstream signalling; Olfactory transduction - Homo sapiens (human);Signaling by GPCR;Signal Transduction;Olfactory Signaling Pathway;G alpha (s) signalling events;GPCR downstream signalling; Oxidative phosphorylation; Gene expression (Transcription);Generic Transcription Pathway;RNA Polymerase II Transcription;Validated transcriptional targets of TAp63 isoforms;Regulation of TP53 Activity through Phosphorylation;Regulation of TP53 Activity;Transcriptional Regulation by TP53; EGFR1; Mitochondrial biogenesis; Human papillomavirus infection - Homo sapiens (human); RIG-I-like receptor signaling pathway - Homo sapiens (human);Human papillomavirus infection - Homo sapiens (human);RIG-I-like Receptor Signaling;Type II interferon signaling (IFNG);DNA Repair;Cytokine Signaling in Immune system;DDX58/IFIH1-mediated induction of interferon-alpha/beta;Innate Immune System;Immune System;Negative regulators of DDX58/IFIH1 signaling;Termination of translesion DNA synthesis;Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template;DNA Damage Bypass;Interferon alpha/beta signaling;ISG15 antiviral mechanism;Antiviral mechanism by IFN-stimulated genes;Interferon Signaling; ECM-receptor interaction - Homo sapiens (human);Primary Focal Segmental Glomerulosclerosis FSGS;Splicing factor NOVA regulated synaptic proteins;Developmental Biology;Signaling by GPCR;Signal Transduction;Metabolism of fat-soluble vitamins;Metabolism of carbohydrates;A tetrasaccharide linker sequence is required for GAG synthesis;HS-GAG biosynthesis;HS-GAG degradation;Heparan sulfate/heparin (HS-GAG) metabolism;Integrin cell surface interactions;Chondroitin sulfate/dermatan sulfate metabolism;Glycosaminoglycan metabolism;Extracellular matrix organization;Metabolism;Metabolism of vitamins and cofactors;Integrin;role of nicotinic acetylcholine receptors in the regulation of apoptosis;agrin in postsynaptic differentiation;NCAM signaling for neurite out-growth;Retinoid metabolism and transport;NCAM1 interactions;Non-integrin membrane-ECM interactions;G alpha (i) signalling events;Axon guidance;Visual phototransduction;ECM proteoglycans;GPCR downstream signalling;Wnt Canonical;Wnt Mammals; MicroRNAs in cancer - Homo sapiens (human);miR-targeted genes in leukocytes - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;miRNA targets in ECM and membrane receptors
108	Pathway(KEGG)_id	dbNSFP	4.0c	KEGG	Y	https://www.genome.jp/dbget-bin/www_bget?<ID>	N	ID(s) of the Pathway(s) the gene belongs to (from KEGG)	hsa04740; hsa04512; hsa04060; hsa00532;hsa01030; Ubiquitin mediated proteolysis - Homo sapiens (human);Protein processing in endoplasmic reticulum - Homo sapiens (human);Parkinson,s disease - Homo sapiens (human);Parkin-Ubiquitin Proteasomal System pathway;Parkinsons Disease Pathway;Post-translational protein modification;protein ubiquitylation;Metabolism of proteins;Immune System;Adaptive Immune System;Antigen processing: Ubiquitination & Proteasome degradation;Class I MHC mediated antigen processing & presentation;Protein ubiquitination;E3 ubiquitin ligases ubiquitinate target proteins; hsa04742; hsa04310;hsa04330;hsa04916;hsa05210;hsa05217; hsa00760; hsa04020;hsa04070;hsa04720;hsa04740;hsa04910;hsa04912;hsa04916;hsa05040;hsa05214; hsa04080
109	Pathway(KEGG)_full	dbNSFP	4.0c	KEGG pathway	Y		N	Full name(s) of the Pathway(s) the gene belongs to (from KEGG)	Olfactory transduction; ECM-receptor interaction; Cytokine-cytokine receptor interaction; Chondroitin sulfate biosynthesis;Glycan structures - biosynthesis 1; hsa04120;hsa05020; Taste transduction; Wnt signaling pathway;Notch signaling pathway;Melanogenesis;Colorectal cancer;Basal cell carcinoma; Nicotinate and nicotinamide metabolism; Calcium signaling pathway;Phosphatidylinositol signaling system;Long-term potentiation;Olfactory transduction;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Huntington's disease;Glioma; Neuroactive ligand-receptor interaction
110	Function_description	dbNSFP	4.0c	Function description	Y		Y	Function description of the gene (from Uniprot)	FUNCTION: Odorant receptor. {ECO:0000305}.; FUNCTION: May play a role in photoreceptor development. {ECO:0000250}.; FUNCTION: Acts as an inhibitor of histone acetyltransferase activity; prevents acetylation of all core histones by the EP300/p300 histone acetyltransferase at p53/TP53-regulated target promoters in a histone deacetylases (HDAC)-independent manner. Acts as a transcription corepressor of p53/TP53- and TP63-mediated transactivation of the p21/CDKN1A promoter. Involved in the regulation of p53/TP53-dependent apoptosis. Associates together with TP63 isoform TA*-gamma to the p21/CDKN1A promoter. {ECO:0000269; FUNCTION: Substrate-recognition component of some cullin-RING- based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. The BCR(KLHL17) mediates the ubiquitination and subsequenct degradation of GLUR6. May play a role in the actin-based neuronal function (By similarity). {ECO:0000250}.; FUNCTION: Controls the stability of the leptin mRNA harboring an AU-rich element (ARE) in its 3' UTR, in cooperation with the RNA stabilizer ELAVL1 (PubMed:29180010). Decreases the stability of the leptin mRNA by antagonizing the function of ELAVL1 by inducing its atypical recruitment from the nucleus to the cytosol (By similarity). Binds to cardiolipin (CL), phosphatidic acid (PA), phosphatidylinositol 4-phosphate (PtdIns(4)P) and phosphatidylserine (PS) (PubMed:18191643). Promotes apoptosis by enhancing BAX-BAK hetro-oligomerization via interaction with BID in colon cancer cells (PubMed:29531808) (By similarity). {ECO:0000250; FUNCTION: Regulates the expression of selective PPARGC1A/B and ESRRA/B/G target genes with roles in glucose and lipid metabolism, energy transfer, contractile function, muscle mitochondrial biogenesis and oxidative capacity. Required for the efficient induction of MT-CO2, MT-CO3, COX4I1, TFB1M, TFB2M, POLRMT and SIRT3 by PPARGC1A. Positively regulates the PPARGC1A/ESRRG-induced expression of CKMT2, TNNI3 and SLC2A4 and negatively regulates the PPARGC1A/ESRRG-induced expression of PDK4. {ECO:0000250; FUNCTION: Transcriptional repressor. Binds DNA on N-box motifs: 5'-CACNAG-3' (By similarity). {ECO:0000250}.; FUNCTION: Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation- inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA- induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity. {ECO:0000269; FUNCTION: Isoform 1: heparan sulfate basal lamina glycoprotein that plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ) and directs key events in postsynaptic differentiation. Component of the AGRN-LRP4 receptor complex that induces the phosphorylation and activation of MUSK. The activation of MUSK in myotubes induces the formation of NMJ by regulating different processes including the transcription of specific genes and the clustering of AChR in the postsynaptic membrane. Calcium ions are required for maximal AChR clustering. AGRN function in neurons is highly regulated by alternative splicing, glycan binding and proteolytic processing. Modulates calcium ion homeostasis in neurons, specifically by inducing an increase in cytoplasmic calcium ions. Functions differentially in the central nervous system (CNS) by inhibiting the alpha(3)- subtype of Na+/K+-ATPase and evoking depolarization at CNS synapses. This secreted isoform forms a bridge, after release from motor neurons, to basal lamina through binding laminin via the NtA domain.; FUNCTION: Isoform 1, isoform 4 and isoform 5: neuron-specific (z+) isoforms that contain C-terminal insertions of 8-19 AA are potent activators of AChR clustering. Isoform 5, agrin (z+8), containing the 8-AA insert, forms a receptor complex in myotubules containing the neuronal AGRN, the muscle-specific kinase MUSK and LRP4, a member of the LDL receptor family. The splicing factors, NOVA1 and NOVA2, regulate AGRN splicing and production of the 'z' isoforms.; FUNCTION: Agrin N-terminal 110 kDa subunit: is involved in regulation of neurite outgrowth probably due to the presence of the glycosaminoglcan (GAG) side chains of heparan and chondroitin sulfate attached to the Ser/Thr- and Gly/Ser-rich regions. Also involved in modulation of growth factor signaling (By similarity). {ECO:0000250, ECO:0000269; FUNCTION: Inactive polyglycylase. {ECO:0000269
111	Disease_description	dbNSFP	4.0c	Disease description	Y		Y	Disease(s) the gene caused or associated with (from Uniprot)	PubMed:16322561, ECO:0000269; UniProtKB:Q8C886, ECO:0000269; UniProtKB:Q149B8}.; PubMed:1373138, ECO:0000269; PubMed:19631309, ECO:0000269; PubMed:19524510}.; PubMed:7704935}.; PubMed:11551958}.; UniProtKB:Q8R2Z0}.; FUNCTION: Catalyzes the covalent attachment of ubiquitin to other proteins. Seems to function in the selective degradation of misfolded membrane proteins from the endoplasmic reticulum (ERAD). {ECO:0000255
112	MIM_phenotype_id	dbNSFP	4.0c	MIM Phenotype ID	Y	https://www.omim.org/entry/<ID>	Y	MIM id(s) of the phenotype the gene caused or associated with (from Uniprot)	PubMed:20123734, ECO:0000269; PubMed:18191643, ECO:0000269; PubMed:16009940, ECO:0000269; PubMed:21969364}.; DISEASE: Immunodeficiency 16 (IMD16) [MIM:615593]: An autosomal recessive primary immunodeficiency associated with classic Kaposi sarcoma of childhood and poor T-cell recall immune responses due to complete functional OX40 deficiency. {ECO:0000269; DISEASE: Spondyloepimetaphyseal dysplasia with joint laxity, 1, with or without fractures (SEMDJL1) [MIM:271640]: A bone disease characterized by vertebral abnormalities and ligamentous laxity that result in spinal misalignment and progressive severe kyphoscoliosis, thoracic asymmetry, and respiratory compromise resulting in early death. Additional skeletal features include elbow deformities with radial head dislocation, dislocated hips, clubfeet, and tapered fingers with spatulate distal phalanges. Many affected children have an oval face, flat midface, prominent eyes with blue sclerae, and a long philtrum. Palatal abnormalities and congenital heart disease are also observed. {ECO:0000269; PROSITE-ProRule:PRU00388}.; PubMed:7499195}.; PubMed:23904267}.; PubMed:28011644, ECO:0000269
113	MIM_disease	dbNSFP	4.0c	MIM Disease	Y		N	MIM disease name(s) with MIM id(s) in '[]' (from Uniprot)	PubMed:20959462}.; PubMed:29180010, ECO:0000269; PubMed:16112642, ECO:0000269; DISEASE: Myasthenic syndrome, congenital, 8 (CMS8) [MIM:615120]: A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS8 is an autosomal recessive disease characterized by prominent defects of both the pre- and postsynaptic regions. Affected individuals have onset of muscle weakness in early childhood; the severity of the weakness and muscles affected is variable. {ECO:0000269; PubMed:23897980}. Note=The disease is caused by mutations affecting the gene represented in this entry.; PubMed:23664117, ECO:0000269; PubMed:29164996}.; PubMed:25817016}. Note=The disease is caused by mutations affecting the gene represented in this entry.; PubMed:22453275}.; PubMed:29053796}. Note=The disease is caused by mutations affecting the gene represented in this entry.
114	Orphanet_disorder_id	dbNSFP	4.0c	Orphanet Disorder ID	Y	https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=<ID>	Y	Orphanet Number of the disorder the gene caused or associated with	PubMed:29531808}.; PubMed:16428300, ECO:0000269; PubMed:19631309, ECO:0000269; 615593; PubMed:23664118}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 616331; 963|2965|314777|314786|314790; DISEASE: Harel-Yoon syndrome (HAYOS) [MIM:617183]: A syndrome characterized by global developmental delay, hypotonia, intellectual disability, and axonal neuropathy. Some patients have optic atrophy and hypertrophic cardiomyopathy. HAYOS inheritance can be autosomal dominant or autosomal recessive. {ECO:0000269; 607454; PubMed:2217177}.
115	Orphanet_disorder	dbNSFP	4.0c	Orphanet Disorder	Y		Y	Disorder name from Orphanet	PubMed:16434471, ECO:0000269; PubMed:22205389, ECO:0000269; 1872; [MIM:615593]Immunodeficiency 16 [recessive?]; 271640|615349; [MIM:616331]Robinow syndrome, autosomal dominant 2 [dominant?]; Acromegaly|Prolactinoma|Familial isolated pituitary adenoma|Silent pituitary adenoma|Null pituitary adenoma; PubMed:27640307}. Note=The disease is caused by mutations affecting the gene represented in this entry.; [MIM:607454]Spinocerebellar ataxia 21; 54260
116	Orphanet_association_type	dbNSFP	4.0c	Orphanet association type	Y		Y	the type of association beteen the gene and the disorder	PubMed:16872604, ECO:0000269; PubMed:24951643}. Note=The disease is caused by mutations affecting the gene represented in this entry.; Cone rod dystrophy; 431149; [MIM:271640]Spondyloepimetaphyseal dysplasia with joint laxity, 1, with or without fractures; 3107; Major susceptibility factor in|Major susceptibility factor in|Disease-causing germline mutation(s) in|Major susceptibility factor in|Major susceptibility factor in; 617183; 98773; Left ventricular noncompaction
117	Trait_association(GWAS)	dbNSFP	4.0c	GWAS catalog trait	Y		Y	Trait(s) the gene associated with (from GWAS catalog)	Subjective response to lithium treatment; Morning vs. evening chronotype; PubMed:18305167, ECO:0000269; 615120; Disease-causing germline mutation(s) (loss of function) in; Inflammatory bowel disease; Combined immunodeficiency due to OX40 deficiency; Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy); 75496|93359; Inflammatory bowel disease|Ulcerative colitis
118	Trait_association(GWAS)_PMID	dbNSFP	4.0c	GWAS catalog trait PMID	Y	https://www.ebi.ac.uk/gwas/publications/<ID>	Y	Trait(s) the gene associated with (from GWAS catalog)	26503763; 26955885; anatomical system; Plekhn1; Medium; 0.88298741376669; 23128233; abnormal; 28067908|28067908; disrupted
119	GO_biological_process	dbNSFP	4.0c	GO biological process	Y		Y	GO terms for biological process	G protein-coupled receptor signaling pathway|detection of chemical stimulus involved in sensory perception of smell; brain development|protein ubiquitination|actin cytoskeleton organization; negative regulation of transcription by RNA polymerase II|somitogenesis|Notch signaling pathway|cell differentiation|regulation of neurogenesis; PubMed:19270716, ECO:0000269; [MIM:615120]Myasthenic syndrome, congenital, 8 [recessive?]; Large artery stroke|Lead levels|Height; positive regulation of leukocyte migration|apoptotic process|signal transduction|tumor necrosis factor-mediated signaling pathway|positive regulation of tyrosine phosphorylation of STAT protein|negative regulation of apoptotic process|regulation of regulatory T cell differentiation|positive regulation of cell adhesion; Disease-causing germline mutation(s) (loss of function) in; UV protection|calcium ion regulated exocytosis|cerebellum development|fat cell differentiation|response to ethanol|zymogen granule exocytosis; Ehlers-Danlos syndrome, progeroid type|Spondyloepimetaphyseal dysplasia with joint laxity
120	GO_cellular_component	dbNSFP	4.0c	GO cellular component	Y		Y	GO terms for cellular component	plasma membrane|integral component of membrane; nucleus; extracellular space|postsynaptic density|actin cytoskeleton|cell junction|dendrite cytoplasm|neuronal cell body|postsynaptic membrane; regulation of transcription, DNA-templated|response to muscle activity; PubMed:19357168, ECO:0000269; 98914|98913; integral component of membrane; protein polyglycylation; extracellular region|plasma membrane|integral component of plasma membrane; Inflammatory bowel disease
121	GO_molecular_function	dbNSFP	4.0c	GO molecular function	Y		Y	GO terms for molecular function	G protein-coupled receptor activity|olfactory receptor activity; Pancreatic cancer; POZ domain binding|protein-containing complex scaffold activity|actin filament binding; nucleus|cytoplasm; RNA polymerase II regulatory region sequence-specific DNA binding|DNA-binding transcription factor activity, RNA polymerase II-specific|transcription corepressor activity|transcription factor binding|sequence-specific DNA binding|protein dimerization activity|sequence-specific double-stranded DNA binding; PubMed:2005397, ECO:0000269; Presynaptic congenital myasthenic syndromes|Postsynaptic congenital myasthenic syndromes; metal ion binding; cytosol; tumor necrosis factor-activated receptor activity|protein binding
122	Tissue_specificity(Uniprot)	dbNSFP	4.0c	Tissue specificity	Y		Y	Tissue specificity description from Uniprot	negative regulation of transcription by RNA polymerase II|negative regulation of B cell apoptotic process|apoptotic process|chromatin assembly|cellular response to UV|negative regulation of histone acetylation|ribosomal large subunit biogenesis|regulation of signal transduction by p53 class mediator|negative regulation of intrinsic apoptotic signaling pathway; Parkinson's disease; PubMed:20133869, ECO:0000269; Disease-causing germline mutation(s) in|Disease-causing germline mutation(s) in; protein binding|ATP binding|protein-glycine ligase activity; Expressed in lymph node, peripheral blood leukocytes and weakly in spleen.; plasma membrane|integral component of plasma membrane|external side of plasma membrane|cell surface; Ubiquitous. Isoform 5 is expressed in pancreas. {ECO:0000269; glycosaminoglycan biosynthetic process|protein glycosylation|heparan sulfate proteoglycan biosynthetic process|glycosaminoglycan metabolic process|chondroitin sulfate biosynthetic process; hormone activity
123	Expression(egenetics)	dbNSFP	4.0c	Expression from egenetics data	Y		Y	Tissues/organs the gene expressed in (egenetics data from BioMart)	skeletal muscle|heart; bone|testis|unclassifiable (Anatomical System); developmental|cochlea|thymus|epididymis|skin|stomach|testis|lens|lymphoreticular|unclassifiable (Anatomical System)|choroid|kidney|larynx|uterus|retina|pancreas|muscle|head and neck|mammary gland|islets of Langerhans|visual apparatus|cervix|fovea centralis|liver|endometrium|bone|germinal center|brain|blood|heart|lung|salivary gland|ovary|macula lutea|lymph node|oesophagus|colon|placenta|prostate|optic nerve|gum; nucleus|nucleoplasm|nucleolus|cytosol|Noc1p-Noc2p complex|Noc2p-Noc3p complex; fovea centralis|cartilage|endometrium|skin|stomach|bone|germinal center|testis|lens|unclassifiable (Anatomical System)|cerebellum|lung|salivary gland|choroid|retina|macula lutea|colon|head and neck|hypopharynx|mammary gland|optic nerve; response to hypoxia|positive regulation of apoptotic process|3'-UTR-mediated mRNA destabilization; Muscle-specific expression is increased by endurance exercise. {ECO:0000269; endometrium|unclassifiable (Anatomical System); PubMed:20308324, ECO:0000269; endometrium|bone|lacrimal gland|testis|brain|unclassifiable (Anatomical System)|heart|lung|kidney|colon|prostate|skeletal muscle|breast|islets of Langerhans
124	Expression(GNF/Atlas)	dbNSFP	4.0c	Expression from GNF/Atlas data	Y		Y	Tissues/organs the gene expressed in (GNF/Atlas data from BioMart)	chromatin binding|transcription corepressor activity|RNA binding|protein binding|nucleosome binding|histone binding|repressing transcription factor binding; ciliary ganglion|pons|subthalamic nucleus|dorsal root ganglion|atrioventricular node|superior cervical ganglion|trigeminal ganglion|globus pallidus; mitochondrion|cytoskeleton|plasma membrane|mitochondrial membrane; PubMed:23836911}.; atrioventricular node|superior cervical ganglion; PubMed:20639253, ECO:0000269; retinoid metabolic process|glycosaminoglycan biosynthetic process|glycosaminoglycan catabolic process|cytoskeleton organization|signal transduction|G protein-coupled acetylcholine receptor signaling pathway|extracellular matrix organization|receptor clustering|positive regulation of GTPase activity|clustering of voltage-gated sodium channels|positive regulation of synaptic growth at neuromuscular junction|positive regulation of transcription by RNA polymerase II|synapse organization|positive regulation of filopodium assembly; superior cervical ganglion|trigeminal ganglion; thymus|spinal ganglion|alveolus|ganglion|skin|stomach|testis|lens|unclassifiable (Anatomical System)|choroid|kidney|uterus|whole body|retina|pancreas|muscle|urinary|mammary gland|trophoblast|islets of Langerhans|visual apparatus|cervix|fovea centralis|iris|spleen|liver|peripheral nerve|cartilage|endometrium|bone|germinal center|parathyroid|brain|blood|heart|bone marrow|lung|salivary gland|ovary|macula lutea|lymph node|oesophagus|colon|placenta|prostate|aorta|optic nerve|medulla oblongata; galactosyltransferase activity|UDP-galactosyltransferase activity|galactosylxylosylprotein 3-beta-galactosyltransferase activity
125	Interactions(IntAct)	dbNSFP	4.0c	IntAct interaction	N		Y	The number of other genes this gene interacting with (from IntAct).	PLEKHF2[unassigned1304]|ECM1[unassigned1304]|KRTAP5-7[unassigned1304]|KRT34[unassigned1304]|TRAF2[unassigned1304]|TSC1[unassigned1304]|TRAF1[unassigned1304]|JMJD7[unassigned1304]|KRT31[unassigned1304]|BPIFA1[unassigned1304]|REL[unassigned1304]|PLAGL2[unassigned1304]|TRIB3[unassigned1304]|PRR20D[unassigned1304]|CCHCR1[unassigned1304]|NFKBID[unassigned1304]|ZMYND12[unassigned1304]|RTL8C[unassigned1304]|GLYR1[unassigned1304]; POM121[unassigned1304]|HGS[unassigned1304]|PCDHB12[unassigned1304]; phosphatidylserine binding|protein binding|phosphatidic acid binding|cardiolipin binding|phosphatidylinositol phosphate binding; EEF1B2[20195357]|HSP90AB1[20195357]|RGS3[20195357]|CMSS1[20195357]|KIF5C[20195357]|LRRIQ1[20195357]|LTN1[20195357]|ATP13A4[20195357]|COPG2[20195357]|ZC3H13[20195357]; PubMed:21543490, ECO:0000269; extracellular region|basement membrane|Golgi lumen|cytosol|plasma membrane|integral component of membrane|cell junction|lysosomal lumen|synapse|collagen-containing extracellular matrix|extracellular exosome; TFRC[unassigned1304]|TOMM6[unassigned1304]; TNFSF18[18040044|18378892]|MYC[21150319]|TNFRSF18[18378892]|UBQLN2[unassigned1304]; thyroid|liver|placenta|prostate|testis; Ubiquitous. {ECO:0000269
126	Interactions(BioGRID)	dbNSFP	4.0c	BioGRID interaction	N		Y	The number of other genes this gene interacting with (from BioGRID)	TNIP2[27609421]|UBC[23314748]; L3MBTL1[28514442]|SAMD7[26186194|28514442]|NCAPH2[28514442]|TRIM25[29117863]|PRR20E[28514442]|SIRT6[28514442]|HNRNPLL[28514442]|ASB3[28514442]; choroid|larynx|epididymis|colon|head and neck|stomach|prostate|testis|unclassifiable (Anatomical System); CUL3[21145461]|KLHL2[28514442]|PDZK1[28514442]|DCN[26186194|28514442]; Ubiquitous (PubMed:18191643). Epressed in several cancer cell lines of differing origin (PubMed:29531808). {ECO:0000269; RGS3[20195357]|SHMT2[22658674]|LTN1[20195357]|PCBD1[20211142]|COPG2[20195357]|PCBD2[20211142]; PubMed:22693631, ECO:0000269; dystroglycan binding|structural constituent of cytoskeleton|extracellular matrix structural constituent|calcium ion binding|protein binding|sialic acid binding|chondroitin sulfate binding|laminin binding|heparan sulfate proteoglycan binding; HNRNPL[28611215]|GBP5[28514442]|ARMC6[28514442]|LGALS8[26186194|28514442]; DDX3X[28431233]|RTCB[28431233]|HNRNPR[28431233]|YBX2[28431233]|ADARB1[28431233]|MSI2[28431233]|YBX1[28431233]|EPRS[28431233]|YBX3[28431233]|EDC4[28431233]|RBM4[28431233]|SYNCRIP[28431233]|PTBP1[28431233]|SART3[28431233]|RARS[28431233]|C1QBP[28431233]|UPF1[28431233]|RBM14[28431233]|AQR[28431233]|RBFOX2[28431233]|PRMT1[28431233]|STRBP[28431233]|PTBP3[28431233]|SFPQ[28431233]|KARS[28431233]|HNRNPH1[28431233]|C9orf114[28431233]|HNRNPH2[28431233]|MATR3[28431233]|PGAM5[28431233]|HNRNPH3[28431233]|SF3B4[28431233]|SF3B2[28431233]|SF3B3[28431233]|DDX1[28431233]|DDX23[28431233]|DDX21[28431233]|NOL6[28431233]|PDCD11[28431233]|PUF60[28431233]|TRA2B[28431233]|DHX36[28431233]|TRA2A[28431233]|G3BP2[28431233]|DHX37[28431233]|IGF2BP1[28431233]|UTP20[28431233]|IGF2BP3[28431233]|IGF2BP2[28431233]|HNRNPA1[28431233]|ZNF346[28431233]|SF3B1[28431233]|HNRNPA0[28431233]|PTCD3[28431233]|DARS[28431233]|SF3A1[28431233]|HNRNPA3[28431233]|CRTAP[28431233]|TAF15[28431233]|FUS[28431233]|NONO[28431233]|KNOP1[28431233]|CDC5L[28431233]|LARP7[28431233]|EIF2AK2[28431233]|ERAL1[28431233]|PUM1[28431233]|U2SURP[28431233]|LRPPRC[28431233]|HNRNPL[28431233]|HNRNPM[28431233]|NUDT21[28431233]|LIN28A[28431233]|HNRNPK[28431233]|QARS[28431233]|HNRNPF[28431233]|MARS[28431233]|HNRNPA2B1[28431233]|FAM98B[28431233]|IARS[28431233]|FAM98A[28431233]|GRSF1[28431233]|APOBEC3B[28431233]
127	Interactions(ConsensusPathDB)	dbNSFP	4.0c	ConsensusPathDB interaction	N		Y	The number of other genes this gene interacting with (from ConsensusPathDB).	RTL8C[0.004]|PROP1[0.958]|REL[0.960]|KRT34[0.267]|PLAGL2[0.958]|ECM1[0.004]|CCHCR1[0.963]|KRT31[0.267]|TRAF1[0.067]|GLYR1[0.960]|TRAF2[0.067]|KRTAP5-7[0.262]|SAMD7[0.004]|L3MBTL1[0.962]|HNRNPLL[0.959]|NCAPH2[0.962]|ASB3[0.004]|SIRT6[0.961]; ACTC1[0.977]|CUL3[0.665]|DCN[0.005]|KLHL2[0.939]|PDZK1[0.955]; PubMed:18191643, ECO:0000269; FAM210B[unassigned1304]|GPR152[unassigned1304]|SLC13A4[unassigned1304]|SLC30A2[unassigned1304]|AQP6[unassigned1304]|SLC16A10[unassigned1304]|PEX12[unassigned1304]|TMEM80[unassigned1304]; RGS3[0.967]|ZC3H13[0.005]|ATP13A4[0.005]|HSP90AB1[0.967]|CMSS1[0.004]|COPG2[0.528]|EEF1B2[0.079]|LTN1[0.005]|LRRIQ1[0.004]|KIF5C[0.317]|PCBD1[0.969]|PCBD2[0.005]; PubMed:22859821, ECO:0000269; Expressed in basement membranes of lung and kidney. Muscle- and neuron-specific isoforms are found. Isoforms (y+) with the 4 AA insert and (z+8) isoforms with the 8 AA insert are all neuron-specific. Isoforms (z+11) are found in both neuronal and non-neuronal tissues. {ECO:0000269; LGALS8[0.004]|ARMC6[0.004]|GBP5[0.218]; RBPMS[25416956]|TRIP6[25416956]|CADPS[25416956]|CEP70[25416956]|FHL3[25416956]|TRIM27[25416956]|PNMA2[25416956]|MDFI[25416956]|KRT40[25416956]|THAP1[25416956]; RUNX1[NA]|CBFB[NA]|FOXP3[NA]|RUNX1[NA]|CBFB[NA]|TNFSF18[0.999]|TRAF2[0.998]|TRAF3[0.993]|TRAF1[0.024]|UBQLN2[0.659]|LNX1[0.055]
128	P(HI)	dbNSFP	4.0c		N		N	Estimated probability of haploinsufficiency of the gene(from doi:10.1371/journal.pgen.1001154)	0.06092; 0.15855; 0.10109; MAGED1[17353931];ILK[17353931];HNRNPU[26496610];FOXQ1[25609649];HIST1H3A[16322561];IFI16[25665578];ATXN7[21078624];MYC[17353931];E2F3[22157815];HIF1AN[26972000];PHLDA3[17353931];NOP56[26496610];FOXB1[25609649];JUN[25609649];BRF2[17353931];EED[26496610];H3F3A[16322561];RPS6[29568061];FOXL1[25609649];RRP1B[20926688];GIPC1[17353931];MNDA[25665578];LRIF1[16189514];HIST2H3D[16322561];PPIB[30021884];TP53[16322561]; 0.09980; PubMed:29531808}.; LMNA[24623722]; 0.20655; PubMed:23229543, ECO:0000269; PubMed:16487930, ECO:0000269
129	HIPred_score	dbNSFP	4.0c		N		N	Estimated probability of haploinsufficiency of the gene(from doi:10.1093/bioinformatics/btx028)	0.186891868710518; 0.263579308986664; HIST2H2AA3[16322561];APP[21832049];EDA[26186194];MPG[23537643];ATN1[16713569];KIAA0020[26344197];ILK[17353931];HNRNPU[26496610];CHD4[28977666];CHD3[28977666];AATF[26344197];FGF3[28514442];RRP8[28514442];FOXQ1[25609649];MECP2[28514442];FBL[26344197];RPS14[28514442];XPO1[26673895];FGF8[28514442];RPL18A[26344197;28514442];PTTG1[30033366];SNAPC1[30033366];DHX15[26344197];RRP12[26344197];CPNE2[28514442];HIF1AN[26972000];MAGEB10[28514442];RBM34[28514442];JAK1[24413661];DDX18[26344197];RBFOX1[16713569];WDR36[26344197];EED[24457600;26496610];ZBTB38[26186194];DDX56[26344197];DDX54[26344197];HIST2H2BA[16322561];SIRT7[22586326];DDX52[26344197];FOXL1[25609649];ILF2[26186194];GTPBP4[26344197];FTSJ3[26344197];EBNA1BP2[26344197];NSA2[26344197];HIST4H4[16322561];DKC1[26344197];GRWD1[26344197];MTF1[28416769];MRTO4[26344197];RPL27[26344197];PLEKHO1[28514442];LRIF1[16189514];ZNF512[28514442];TP53[20959462;16322561];OBSL1[24711643];GLYR1[26344197];CUL7[24711643];DDX24[26344197];MAGED1[17353931];SHMT2[22658674];NOP2[26344197];MAK16[28514442];PDGFB[28514442];RPF2[26344197];SDAD1[26344197];RNF4[29180619];AURKB[20959462];RNF2[24457600];NOL6[26344197];NXF1[22658674];IFI16[25693804];ATXN7[21078624];PES1[26344197;25825154];RRS1[26344197];ZNF746[25315684];RPL18[28514442];SCN3B[28514442];NTRK1[25921289];NOP56[26496610];FOXB1[25609649];NPM1[26186194;28514442];BRF2[17353931];NIFK[26344197];PYHIN1[28077445];DDX31[26344197];PPP1CA[10637318];MOV10[22658674];TBL3[26344197];CCDC8[24711643];HIST3H3[16322561];MDM2[24413661];CEBPZ[26344197]; 0.352169781923294; SLC30A2[0.004];SLC13A4[0.004];LMNA[0.004]; 0.285495072603226; PubMed:7526157, ECO:0000269; PubMed:20551380, ECO:0000269; 0.146139457821846; 0.11164
130	HIPred	dbNSFP	4.0c		N		N	HIPred prediction of haploinsufficiency of the gene. Y(es) or N(o).(from doi:10.1093/bioinformatics/btx028)	N; TP53[0.999];TP53[NA];AURKB[NA];TP63[0.999];EED[0.999];ATXN7[0.992];BRF2[0.999];PHLDA3[0.366];ATP1A1[NA];KRT1[NA];SUN2[NA];INTS5[NA];SEC61A1[NA];INTS3[NA];KDM1A[NA];AGPAT5[NA];HSPA5[NA];GPAM[NA];SHOC2[NA];KRT14[NA];ALB[NA];MSH6[NA];LMNA[NA];HELLS[NA];PARP1[NA];SCD[NA];IMPA1[NA];MYO1C[NA];PGAP1[NA];GTPBP2[NA];HNRNPU[NA];E2F3[NA];XRCC5[NA];SLC25A10[NA];DHX33[NA];EFTUD2[NA];NUP93[NA];RBSN[NA];INTS6[NA];PRKDC[NA];SLC2A1[NA];IMMT[NA];AKAP8[NA];POLG[NA];CTNNB1[NA];CTNNA1[NA];SMARCA1[NA];KRT9[NA];MYO1B[NA];ATP2A2[NA];L3MBTL3[NA];TRIM28[NA];MRPL57[NA];NDUFS1[NA];SLC25A5[NA];RAB13[NA];MSH2[NA];ITGB1[NA];NAT10[NA];NOLC1[NA];TRRAP[NA];AHCTF1[NA];SLC27A4[NA];SMPD4[NA];DDX41[NA];NUMA1[NA];WRN[NA];SFMBT1[NA];AFG3L2[NA];MYBBP1A[NA];SLC25A4[NA];ENOX2[NA];TFRC[NA];HSPA9[NA];KAT2A[NA];SP1[NA];SLC25A3[NA];RHOT1[NA];ZBED4[NA];GPD2[NA];LRPPRC[NA];LBR[NA];TCERG1[NA];ACADS[NA];NOTCH3[NA];ALPI[NA];SLC25A6[NA];TRIM23[NA];EEF1A1[NA];PMM1[NA];ATAD3A[NA];RPS27L[NA];DDB1[NA];CPT1A[NA];HADHA[NA];TMEM33[NA];CCDC9[NA];NCL[NA];MYO6[NA];CEBPZ[NA];NPLOC4[NA];TCF7L2[NA];DDX21[NA];ZNF148[NA];RB1[NA];TNXB[NA];HSPA6[NA];CLASP1[NA];HLTF[NA];MATR3[NA];TECR[NA];STT3A[NA];RPS3[NA];SLC16A3[NA];DOCK8[NA];RFC1[NA];NUP98[NA];NUP205[NA];DHX9[NA];DHCR7[NA];XRCC6[NA];RHOT2[NA];ZNF300[NA];PCLO[NA];ADGRF5[NA];NCAPG[NA];ZC3H11A[NA];SYMPK[NA];FOXL1[NA];YY1[NA];SIX5[NA];ORC3[NA];IARS[NA];INTS3[NA];STOM[NA];NOVA1[NA];RAD50[NA];NELFCD[NA];RANBP2[NA];ECPAS[NA];TOMM70[NA];SMARCA5[NA];MDN1[NA];DDX39A[NA];BTAF1[NA];SATB1[NA];RMDN3[NA];PI4KA[NA];YARS[NA];HELLS[NA];ARID3B[NA];RANGAP1[NA];UBE4A[NA];RALY[NA];GTF3C5[NA];TOMM40[NA];ADAR[NA];LMNB2[NA];ORC4[NA];DARS2[NA];SCRIB[NA];UTP6[NA];MRPS30[NA];SMC3[NA];GTF3C1[NA];NR2F1[NA];IRF9[NA];CHD1L[NA];PDS5A[NA];DCUN1D5[NA];CPSF2[NA];SMC4[NA];NR2C2[NA];KIF22[NA];NCAPD2[NA];CKAP5[NA];GBF1[NA];HK2[NA];DYNC1H1[NA];ZFHX4[NA];POLE[NA];SMARCA1[NA];NEMP1[NA];NCAPH[NA];SNX2[NA];NSF[NA];GTF3C4[NA];EEF1D[NA];ARID3A[NA];STAG1[NA];AARS2[NA];SMPD4[NA];SMC1A[NA];FASN[NA];SPIDR[NA];SATB2[NA];CENPB[NA];ORC2[NA];FEN1[NA];HEATR1[NA];EIF4G1[NA];NSDHL[NA];HSPA14[NA];HDAC2[NA];HDAC6[NA];PA2G4[NA];SMC2[NA];RIF1[NA];MRPL45[NA];BAZ1A[NA];UTP20[NA];ABCF3[NA];NR3C1[NA];NOL9[NA];TLE3[NA];SMARCAD1[NA];HK3[NA];NUP133[NA];RINT1[NA];COPA[NA];GADD45GIP1[NA];MAP2K3[NA];NUP98[NA];NUP205[NA];DHFR[NA];UFL1[NA];VARS[NA];MRPL38[NA];GAPVD1[NA];NCAPG[NA];COG5[NA];H3F3A[0.999];HIST2H3A[0.999];RANBP2[NA];SMARCA5[NA];DDX39A[NA];SATB1[NA];BTAF1[NA];SYMPK[NA];ORC3[NA];RBBP5[NA];IARS[NA];LRWD1[NA];ACSL4[NA];GTF3C5[NA];ZMYM3[NA];GTF3C1[NA];HELLS[NA];YARS[NA];MCM6[NA];GATAD2B[NA];SF3B2[NA];UBE4A[NA];RANGAP1[NA];PBX1[NA];SF3A1[NA];PUM1[NA];KIF22[NA];CHD4[NA];NUP85[NA];CUX1[NA];SF3A3[NA];CTBP2[NA];PDS5A[NA];SMC4[NA];KIF1BP[NA];ANAPC7[NA];POGZ[NA];SMC1A[NA];ASH2L[NA];SATB2[NA];ORC2[NA];ZNF326[NA];HEATR1[NA];SF3B1[NA];CDC27[NA];GTF3C3[NA];MYO1A[NA];ZFR[NA];SMARCA1[NA];GTF3C2[NA];POLE[NA];RCC1[NA];NSF[NA];NDUFV1[NA];ZMYM2[NA];CCAR2[NA];GTF3C4[NA];FUBP3[NA];FOXQ1[NA];SMC2[NA];ADNP[NA];NUP160[NA];NUP107[NA];NUP133[NA];HIC2[NA];COPA[NA];ZBTB33[NA];TLE3[NA];HNRNPUL2[NA];ZNF143[NA];VARS[NA];HOXD13[NA];TFCP2[NA];KIF5B[NA];NUP98[NA];NUP205[NA];HIST1H3A[0.999];CNOT1[NA];PHACTR4[NA];NOTCH2[NA];BLM[NA];CEP89[NA];KCTD15[NA];NFKBIA[NA];ZRANB2[NA];NCKAP5L[NA];HIF1A[NA];NKAPD1[NA];RAVER2[NA];QRICH1[NA];TMCO1[NA];ASB6[NA];IFRD2[NA];HBS1L[NA];MAP3K21[NA];PPP6R1[NA];TCF12[NA];CNN2[NA];RPL37[NA];SSR3[NA];ZGPAT[NA];EIF4E[NA];PSMC5[NA];HACE1[NA];PSMD10[NA];PLCH1[NA];ASB13[NA];PFKM[NA];RTFDC1[NA];HDAC3[NA];EIF4ENIF1[NA];CASKIN2[NA];RELA[NA];DNAJB6[NA];NDUFAF4[NA];ANKRD44[NA];MAEA[NA];LZTS2[NA];SYNE2[NA];RAVER1[NA];TNKS[NA];RPS24[NA];ATAD1[NA];PPM1G[NA];ELOC[NA];NCOA3[NA];KIDINS220[NA];ANKFY1[NA];BTF3[NA];ZCCHC14[NA];CDC20[NA];TRMT10C[NA];NFKB2[NA];EXD2[NA];RNASEL[NA];TNRC6B[NA];GMDS[NA];SEC61B[NA];GPATCH8[NA];MTCH1[NA];TANK[NA];KDM3B[NA];ANKRD28[NA];OSBPL1A[NA];LSM11[NA];MAP3K7[NA];CEP350[NA];RPL27[NA];RIPK4[NA];HDLBP[NA];ELOB[NA];HIF1AN[NA];TLN2[NA];COPG1[NA];PSMC2[NA];ANKHD1[NA];CCAR2[NA];CFAP44[NA];PPP6R3[NA];SIK3[NA];NT5DC2[NA];ANKRD27[NA];ATAD3A[NA];ANKEF1[NA];ZNF622[NA];RRP8[NA];ASB8[NA];MIB2[NA];MLF2[NA];WDR77[NA];PARP8[NA];PSMD14[NA];NOTCH3[NA];HECTD1[NA];ZCCHC3[NA];RPS15[NA];POLR2B[NA];ARNT[NA];ILK[NA];EHMT1[NA];UBAP2L[NA];TNKS2[NA];VAPA[NA];ANKRD52[NA];ZBTB33[NA];EDC3[NA];CNOT11[NA];NFKBIE[NA];ANKS6[NA];HAUS4[NA];MORC4[NA];FMR1[NA];PLA2G6[NA];ANKRD50[NA];PSMD13[NA];RPRD2[NA];ANKS1A[NA];POLR2L[NA];ANKRD17[NA];NAA10[NA];ZNF131[NA];NCAPH[NA];POLE[NA];GTF3C3[NA];TLE4[NA];ZFR[NA];HK2[NA];DYNC1H1[NA];HEATR1[NA];MRPL27[NA];SATB2[NA];SMC1A[NA];SMPD4[NA];AARS2[NA];EEF1D[NA];ARID3A[NA];SMC4[NA];CTBP2[NA];PDS5A[NA];UBR5[NA];NDUFV2[NA];E4F1[NA];SF3A3[NA];GBF1[NA];NCAPD2[NA];IQGAP2[NA];WAPL[NA];SACM1L[NA];CTNND1[NA];ZBTB40[NA];UBE4A[NA];RALY[NA];RANGAP1[NA];ARID3B[NA];YARS[NA];GTF3C1[NA];MRPS30[NA];SMC3[NA];SCRIB[NA];DARS2[NA];STAG2[NA];ADAR[NA];DARS[NA];HK3[NA];GTF3C5[NA];TOMM40[NA];NOVA1[NA];LRWD1[NA];NUP160[NA];MRPL45[NA];MRPL24[NA];MRPL20[NA];RIF1[NA];IARS[NA];PA2G4[NA];SMC2[NA];ANP32C[NA];SIX5[NA];SYMPK[NA];NSDHL[NA];YY1[NA];HUWE1[NA];SATB1[NA];BTAF1[NA];DDX39A[NA];PRPF31[NA];SMARCA5[NA];MRPL51[NA];ECPAS[NA];RANBP2[NA];FUBP3[NA];GTF3C4[NA];COPG1[NA];CCAR2[NA];RCC1[NA];GTF3C2[NA];CTNNB1[NA];SALL1[NA];ZFHX4[NA];SF3B1[NA];DUSP9[NA];EIF4G1[NA];NOVA2[NA];FOXB1[NA];SKP2[NA];HOXA10[NA];QARS[NA];DHFR[NA];UFL1[NA];NUP205[NA];LARS[NA];TP53[NA];MRPL3[NA];GAPVD1[NA];MRPL18[NA];COG5[NA];MRPL38[NA];HOXD13[NA];VARS[NA];MEN1[NA];HNRNPUL2[NA];KPNA1[NA];TLE3[NA];MRPL50[NA];LRP1[NA];ZBTB33[NA];TFAP2A[NA];GADD45GIP1[NA];COPA[NA];HIC2[NA];TLE1[NA];ILK[0.629];MAGED1[0.656];GIPC1[0.292];NOL10[NA];SPOUT1[NA];WDR3[NA];RPF2[NA];GAR1[NA];RRP1[NA];GPATCH4[NA];DDX47[NA];PWP1[NA];ATXN2L[NA];REXO4[NA];NVL[NA];RBM19[NA];RBM34[NA];DDX24[NA];POP1[NA];KRR1[NA];BYSL[NA];IGF2BP3[NA];RBM28[NA];CCDC86[NA];NOL11[NA];FAM120A[NA];DDX52[NA];UTP14A[NA];DDX27[NA];C7orf50[NA];UTP18[NA];H2AFX[NA];SDC1[NA];SURF6[NA];ISG20L2[NA];HP1BP3[NA];LARP1[NA];CAPRIN1[NA];MAK16[NA];NOP10[NA];RPF1[NA];STRBP[NA];UTP15[NA];NKRF[NA];SPATS2L[NA];CCDC137[NA];EXOSC2[NA];LARP4B[NA];NOP16[NA];EXOSC10[NA];PELP1[NA];PES1[NA];RRP15[NA];DDX54[NA];NSD2[NA];DHX30[NA];DHX33[NA];USP36[NA];DDX50[NA];NIFK[NA];H1FX[NA];GLYR1[NA];NOP56[NA];NOL8[NA];RPP30[NA];CENPV[NA];LARP4[NA];RRP12[NA];BRIX1[NA];WDR12[NA];NAT10[NA];PABPC1[NA];DDX31[NA];CTCF[NA];LENG8[NA];ATXN2[NA];TENT4B[NA];LARP7[NA];MYBBP1A[NA];URB1[NA];RRP1B[NA];AATF[NA];PABPC4[NA];YTHDC2[NA];DKC1[NA];NHP2[NA];PDCD11[NA];ZNF711[NA];GRWD1[NA];RRP8[NA];KNOP1[NA];DHX57[NA];NOC3L[NA];TEX10[NA];PAK1IP1[NA];DDX51[NA];MNDA[NA];LAS1L[NA];ZC3HAV1[NA];ZCCHC3[NA];NOP53[NA];NOL6[NA];EXOSC6[NA];FTSJ3[NA];RRP7A[NA];XRN2[NA];PPP1CB[NA];UTP20[NA];RRS1[NA];EIF3A[NA];NSA2[NA];RACK1[NA];KRI1[NA];BOP1[NA];EXOSC7[NA];GTPBP4[NA];NOL9[NA];NOP2[NA];PLS3[NA];HIST1H1E[NA];PPAN[NA];STAU2[NA];WDR36[NA];EXOSC3[NA];UPF1[NA];STAU1[NA];DDX18[NA];RIOX1[NA];IGF2BP1[NA];DDX21[NA];GNL3[NA];CEBPZ[NA];PPP1CC[NA];COPA[NA];DDX6[NA];NGDN[NA];NOP58[NA];PUM3[NA];RCN2[NA];DDX10[NA];TRMT1L[NA];RSL1D1[NA];MTREX[NA];EBNA1BP2[NA];PNP[NA];CASC3[NA];GNL2[NA];MRTO4[NA];BMS1[NA];MKI67[NA];TBL3[NA];LYAR[NA];MOV10[NA];WDR75[NA];FBL[NA];URB2[NA];MYC[0.999];RPL5[NA];USP36[NA];RPL7L1[NA];FBL[NA];MOV10[NA];TBL3[NA];LYAR[NA];ACACB[NA];MKI67[NA];BMS1[NA];MRTO4[NA];NMNAT1[NA];GNL2[NA];EBNA1BP2[NA];PRKRA[NA];RSL1D1[NA];DHX37[NA];RFC1[NA];TRMT1L[NA];NUP205[NA];REPIN1[NA];DDX10[NA];RPS13[NA];RPL10A[NA];PUM3[NA];NGDN[NA];RPL31[NA];RSBN1[NA];ELOA[NA];RPLP0[NA];PDCD11[NA];RPL13[NA];LLPH[NA];PWP2[NA];GZF1[NA];NOL12[NA];MRPL11[NA];TSR1[NA];AATF[NA];MRPS31[NA];MYBBP1A[NA];RRP1B[NA];MRPS15[NA];RPL36A[NA];NIP7[NA];CTCF[NA];NAT10[NA];BRIX1[NA];RPL26L1[NA];WDR12[NA];ECH1[NA];DDX55[NA];NOL8[NA];H1FX[NA];NOP56[NA];BOP1[NA];RPL19[NA];ARF4[NA];KRI1[NA];RPS14[NA];LACTB[NA];RPL17[NA];UTP20[NA];RRS1[NA];ZNF512[NA];FANCI[NA];RRBP1[NA];RPL39[NA];FTSJ3[NA];NOL6[NA];MRPL24[NA];NOP53[NA];ZC3HAV1[NA];RPLP2[NA];LAS1L[NA];DDX51[NA];PAK1IP1[NA];TEX10[NA];RPL7A[NA];NOC3L[NA];MRPS34[NA];KNOP1[NA];RRP8[NA];GRWD1[NA];ESF1[NA];RPS9[NA];RPS23[NA];NOL10[NA];POLRMT[NA];SDAD1[NA];RPL18A[NA];RFC4[NA];MAK16[NA];SRP72[NA];MRPS16[NA];SLC25A1[NA];HADHB[NA];UTP23[NA];RPL3[NA];EIF6[NA];RPL32[NA];CEBPZ[NA];GNL3[NA];RSL24D1[NA];DDX21[NA];RPL35A[NA];RPL18[NA];MPHOSPH10[NA];ZNF286A[NA];DDX18[NA];GRPEL1[NA];STAU1[NA];RIOX1[NA];MRPL47[NA];NOM1[NA];RPLP1[NA];RPS17[NA];WDR36[NA];MRPL28[NA];MRPS10[NA];PPAN[NA];SLC39A7[NA];RPL4[NA];RPL14[NA];RPS6[NA];RPL36[NA];PTCD3[NA];NCL[NA];MRPS25[NA];NOP14[NA];RPL12[NA];MRPS26[NA];NEPRO[NA];RPL7[NA];HP1BP3[NA];SURF6[NA];HAGH[NA];NOP2[NA];DDX56[NA];WDR18[NA];HADHA[NA];C7orf50[NA];NOL9[NA];RPL13A[NA];GTPBP4[NA];DDX27[NA];DAP3[NA];NIFK[NA];DDX50[NA];SRP68[NA];DHX33[NA];RCL1[NA];DIEXF[NA];NUP188[NA];DHX30[NA];DDX54[NA];RPL37A[NA];RPS8[NA];RRP15[NA];PES1[NA];PELP1[NA];NPM3[NA];WDR43[NA];MRPS22[NA];NOP16[NA];EXOSC10[NA];UTP3[NA];RPS3A[NA];RPS24[NA];MCCC1[NA];CCDC137[NA];MAP7D1[NA];RPL30[NA];NKRF[NA];RPL26[NA];IMP3[NA];IMP4[NA];NOC4L[NA];EMD[NA];DIMT1[NA];HEATR1[NA];RPS4X[NA];BCCIP[NA];RPL28[NA];URB1[NA];ATP2A2[NA];RPL8[NA];DDX31[NA];RRP12[NA];PARN[NA];AKAP8L[NA];GTF3C3[NA];RPP30[NA];GLYR1[NA];LIN28B[NA];NSUN2[NA];DDX52[NA];CCDC86[NA];PCID2[NA];MRPS5[NA];IGF2BP3[NA];RBM28[NA];POP1[NA];KRR1[NA];BYSL[NA];DDX24[NA];MRPS18B[NA];RPL6[NA];RFC3[NA];RBM34[NA];RPL11[NA];ZKSCAN8[NA];NVL[NA];RBM19[NA];REXO4[NA];PWP1[NA];RRP1[NA];ABT1[NA];GPATCH4[NA];RPF2[NA];LTV1[NA];MRPS27[NA];WDR3[NA];RPL29[NA];LRIF1[0.999];DHX57[NA];ERCC6[NA];RPL7A[NA];NOL6[NA];SOGA1[NA];LSG1[NA];RPS14[NA];RPS25[NA];RARS[NA];KRI1[NA];RTRAF[NA];EIF2S3[NA];JADE2[NA];GTPBP4[NA];NOP2[NA];PINX1[NA];RPL7[NA];RPS6[NA];PPAN[NA];RPS27[NA];WDR36[NA];DDX18[NA];RIOX1[NA];MRM1[NA];DDX21[NA];GNL3[NA];RPS15A[NA];CEBPZ[NA];RFC4[NA];RPLP0[NA];RPS3[NA];NOP58[NA];TOP2A[NA];C8orf33[NA];RPL10A[NA];DDX10[NA];CDC6[NA];MEPCE[NA];DHX37[NA];RFC1[NA];RSL1D1[NA];EBNA1BP2[NA];MAP3K1[NA];DHX9[NA];MRTO4[NA];MKI67[NA];TBL3[NA];LYAR[NA];MLLT6[NA];FBL[NA];URB2[NA];HSD17B10[NA];RPL5[NA];LEMD2[NA];H1FX[NA];GLYR1[NA];NOP56[NA];FAM111A[NA];DDX55[NA];CENPV[NA];RPL22[NA];RRP12[NA];BRIX1[NA];EXOSC9[NA];NAT10[NA];GTF3C4[NA];PRRC2A[NA];USP10[NA];NIP7[NA];RPL8[NA];DECR1[NA];RPL23A[NA];MYBBP1A[NA];CCDC124[NA];URB1[NA];TRMT10C[NA];TSR1[NA];WDR74[NA];RPS4X[NA];CIRBP[NA];RPS2[NA];EIF2B1[NA];WDR3[NA];RPL11[NA];RFC3[NA];RPL6[NA];POP1[NA];RBM28[NA];RPL23[NA];RFC5[NA];ABCF1[NA];RFC2[NA];RPS12[NA];RPL13A[NA];C7orf50[NA];UBTF[NA];LARP1[NA];ATAD5[NA];RPL12[NA];RPL36[NA];RPL4[NA];RPL32[NA];RPL3[NA];IBTK[NA];SAMD1[NA];EIF2B4[NA];NOP10[NA];CCDC137[NA];RPL30[NA];RPS24[NA];RPS3A[NA];PNMA3[NA];RPL24[NA];NOP16[NA];RIOX2[NA];DEK[NA];UTP4[NA];RRP15[NA];DDX54[NA];DHX30[NA];NMT1[NA];SRP68[NA];DHX33[NA];LAS1L[NA];ZCCHC3[NA];TEX10[NA];NOL6[NA];EXOSC6[NA];FTSJ3[NA];NOP53[NA];PNO1[NA];TRIP12[NA];NOC3L[NA];CACYBP[NA];KRI1[NA];RACK1[NA];NSA2[NA];S100A8[NA];HSPA4L[NA];G3BP1[NA];BOP1[NA];CTSD[NA];EIF3A[NA];RRS1[NA];UTP20[NA];DCAF13[NA];NOP14[NA];PPAN[NA];HIST1H1E[NA];GTPBP4[NA];SRRM2[NA];NOP2[NA];NARS[NA];DNAJC9[NA];COPA[NA];PELO[NA];ZMPSTE24[NA];DDX18[NA];UPF1[NA];ATXN10[NA];WDR36[NA];GNL3[NA];CEBPZ[NA];DDX21[NA];RCC2[NA];TRMT1L[NA];RCN2[NA];DDX10[NA];WDR46[NA];NGDN[NA];PUM3[NA];ACTR3[NA];NOP58[NA];PHIP[NA];MOV10[NA];WDR75[NA];MKI67[NA];BMS1[NA];LYAR[NA];TBL3[NA];KIF5B[NA];SNRNP70[NA];VARS[NA];PNP[NA];RSL1D1[NA];MTREX[NA];MAP1B[NA];EBNA1BP2[NA];MRTO4[NA];XRCC6[NA];UTP4[NA];PES1[NA];PELP1[NA];RRP15[NA];GNL2[NA];PABPC1[NA];CCAR2[NA];S100A9[NA];USP10[NA];RANBP1[NA];NAT10[NA];DNMT1[NA];SERBP1[NA];CENPV[NA];H1FX[NA];TBCB[NA];WDR12[NA];BRIX1[NA];RRP12[NA];FEN1[NA];PDIA4[NA];UCHL1[NA];PWP2[NA];HIST1H1C[NA];LLPH[NA];DKC1[NA];MAT2A[NA];PDCD11[NA];EIF3L[NA];MCM4[NA];MYBBP1A[NA];C1QBP[NA];SAFB[NA];SARS2[NA];BTF3[NA];PABPC4[NA];TSR1[NA];HELZ[NA];NVL[NA];RRP1[NA];PWP1[NA];RBM34[NA];IFI16[NA];NUFIP2[NA];NOL10[NA];EMG1[NA];RPF2[NA];NOL11[NA];MSH6[NA];ATIC[NA];UTP14A[NA];NSUN2[NA];ABCF1[NA];SMARCA5[NA];DDX24[NA];KRR1[NA];POP1[NA];RBM28[NA];SLTM[NA];USP7[NA];PEG10[NA];C7orf50[NA];DDX27[NA];HP1BP3[NA];H2AFX[NA];CAPRIN1[NA];MAK16[NA];UTP6[NA];NUDT5[NA];ADAR[NA];MPHOSPH10[NA];PPM1G[NA];LARP4B[NA];DNTTIP2[NA];FKBP4[NA];NKRF[NA];RNH1[NA];NIFK[NA];DDX50[NA];SAFB2[NA];CHD4[NA];HAT1[NA];EXOSC10[NA];NOP16[NA];WDR43[NA];XRCC5[NA];EIF3C[NA];DDX54[NA];RRP9[NA];ABCF1[NA];LCOR[NA];PHF19[NA];RPL9[NA];SUZ12[NA];TCEA1[NA];AEBP2[NA];DDX21[NA];EZH2[NA];TFAP2A[NA];NOP2[NA];GTPBP4[NA];JARID2[NA];DDX10[NA];EPOP[NA];RBBP7[NA];EED[NA];PHF1[NA];MTF2[NA];RBBP4[NA];RBFOX1[0.936];ATN1[0.949];PPP1CA[0.993];AURKB[0.999];SIRT7[0.999];HIST3H3[0.999];HIST2H2AA3[0.015];HIST1H4A[0.017];APP[0.328];MPG[0.999];MDM2[0.999];JAK1[0.805];CUL7[0.990];OBSL1[0.934];CCDC8[0.032];RNF2[0.999];NPM1[0.999];ZBTB38[0.940];ILF2[0.999];EDA[0.355];CEBPZ[0.986];DDX52[0.999];DDX54[0.999];NIFK[0.999];AATF[0.997];DDX18[0.999];DDX24[0.999];DDX31[0.999];DDX56[0.999];DHX15[0.999];DKC1[0.999];EBNA1BP2[0.999];FBL[0.999];FTSJ3[0.999];GLYR1[0.979];GRWD1[0.999];GTPBP4[0.999];PUM3[0.999];MRTO4[0.999];NOP2[0.999];NSA2[0.999];PES1[0.999];RPL18A[0.999];RPL27[0.998];RRP12[0.997];RRS1[0.999];TBL3[0.999];WDR36[0.034];NOL6[0.999];RPF2[0.999];SDAD1[0.999];NTRK1[0.716];IFI16[0.999];XPO1[0.999];HNRNPU[0.999];NOP56[0.999];FOXB1[0.999];FOXL1[0.999];FOXQ1[0.999];ZNF746[0.993];MAK16[0.999];RPL18[0.997];MAGEB10[0.005];FGF8[0.006];RPS14[0.999];PDGFB[0.885];FGF3[0.304];PLEKHO1[0.797];RRP8[0.999];RBM34[0.999];MECP2[0.991];SCN3B[0.323];ZNF512[0.944];CPNE2[0.005];MTF1[0.939]; 0.06703; PubMed:8550581}.; PubMed:9652404}.; 0.146139457821846; 0.08629; 0.309710115194321; PEX19[26186194;28514442];XRN1[15231747];KCNA10[28514442];SYNE4[26186194;28514442];SCN3B[28514442];MCPH1[29150431]; 0.10943
131	GHIS	dbNSFP	4.0c		N		N	A score predicting the gene haploinsufficiency. The higher the score the more likely the gene is haploinsufficient. (from doi: 10.1093/nar/gkv474)	0.24042; 0.641794967; PRKAA2[unassigned1304];USP54[unassigned1304];PPP1R32[unassigned1304];CALCOCO2[unassigned1304];PXN[unassigned1304];AKAP8L[unassigned1304];PPM1J[unassigned1304];FHL5[unassigned1304];KRT83[unassigned1304];CYSRT1[unassigned1304];ATXN1[unassigned1304];TP53BP2[25416956;unassigned1304];KRTAP6-2[unassigned1304];LPXN[25416956;unassigned1304];HOXA1[unassigned1304];TRIM27[25416956];LZTS2[25416956];PPP1R16B[unassigned1304];WWOX[unassigned1304];ZRANB1[unassigned1304];ARID5A[unassigned1304];MTUS2[unassigned1304];TRAF1[25416956;unassigned1304];NOTCH2NLA[unassigned1304];KRT31[unassigned1304];KRTAP19-6[unassigned1304];SORBS3[unassigned1304];RFX6[25416956];ABI2[unassigned1304];TRIP6[unassigned1304];KRT36[unassigned1304];REL[25416956;unassigned1304];TAX1BP1[25416956;unassigned1304];ZNF438[unassigned1304];TCF4[25416956];SPERT[25416956;unassigned1304];NFKBID[unassigned1304];GLYR1[unassigned1304]; 0.480431284; DISEASE: Immunodeficiency 38, with basal ganglia calcification (IMD38) [MIM:616126]: A primary immunodeficiency predisposing individuals to severe clinical disease upon infection with weakly virulent mycobacteria, including Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccines. Patients are also susceptible to Salmonella and Mycobacterium tubercolosis infections. Affected individuals have intracranial calcification. {ECO:0000269; 0.443129556; 0.530395714; N; 0.146139457821846; XRN1[0.984];PEX19[0.954];SYNE4[0.989];SCN3B[0.753];KCNA10[0.749];MCPH1[0.375]
132	P(rec)	dbNSFP	4.0c		N		N	Estimated probability that gene is a recessive disease gene (from DOI:10.1126/science.1215040)	0.07159; 0.08067; 0.51941329240799; 0.09909; RFX6[25416956];REL[25416956];TP53BP2[25416956];TAX1BP1[25416956];LPXN[25416956];TCF4[25416956];TRIM27[25416956];TRAF1[25416956];LZTS2[25416956];SPERT[25416956]; 0.11867; PubMed:22859821}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 0.16362; N; 0.585766194
133	Known_rec_info	dbNSFP	4.0c	Known recessive status	Y		N	Known recessive status of the gene (f2rom DOI:10.1126/science.1215040);lof-tolerant = seen in homozygous state in at least one 1000G individual;recessive = known OMIM recessive disease	Y; TRAF1[0.005];TRIP6[0.024];KRT36[0.004];TAX1BP1[0.005];KRT83[0.005];WWOX[0.004];AKAP8L[0.004];USP54[0.004];PRKAA2[0.019];ATXN1[0.005];TCF4[0.004];KRTAP6-2[0.005];TP53BP2[0.004];PPP1R32[0.006];LPXN[0.006];LZTS2[0.005];RFX6[0.005];HOXA1[0.005];KRTAP19-6[0.005];MTUS2[0.004];ZRANB1[0.004];CALCOCO2[0.013];REL[0.005];ARID5A[0.005];SORBS3[0.005];CYSRT1[0.015];SPERT[0.005];KRT31[0.005];NCK2[0.014];TRIM27[0.005];ABI2[0.005];CCDC57[0.004];DEF6[0.004];PPM1J[0.004];GLYR1[0.004];PXN[0.012]; 0.551744031; 616126; PDIA3[17170699];TEPSIN[unassigned1304];APP[10673326;28106549];GFI1B[16713569];BOLL[unassigned1304];NUDCD1[29021621];ATXN7[21078624];MAGED1[unassigned1304];PYHIN1[25665578];ATN1[16713569];DAG1[unassigned1793];CACNA1A[21078624]; 0.35502; 0.428727090358734; 0.405869786; 0.656144806; 0.419153175
134	RVIS_EVS	dbNSFP	4.0c	RVIS(ESP6500)	Y		N	Residual Variation Intolerance Score, a measure of intolerance of mutational burden, the higher the score the more tolerant to mutational burden the gene is. Based on EVS (ESP6500) data. from doi:10.1371/journal.pgen.1003709	0.526388187; -2.65; 0.19904; [MIM:616126]Immunodeficiency 38, with basal ganglia calcification; PDIA3[17170699];CRP[28514442];PYHIN1[28077445];ATN1[16713569];CACNA1A[21078624];TUBG1[23443559];SKI[25670202];MOV10[22658674];NXF1[22658674];GFI1B[16713569];OLFM3[28514442];ZFP41[26186194;28514442];CAMKV[28514442];OS9[28514442];ATXN7[21078624];UBC[28190767];DAG1[8205617]; -0.23; N; 0.09401; 0.14008; -0.35
135	RVIS_percentile_EVS	dbNSFP	4.0c	RVIS(ESP6500) percentile	Y		N	The percentile rank of the gene based on RVIS, the higher the percentile the more tolerant to mutational burden the gene is. Based on EVS (ESP6500) data.	0.13894; 0.75; 0.146139457821846; 319563; NCAM1[0.998];DAG1[0.991];LRP4[NA];MUSK[NA];MUSK[NA];SRC[NA];RAPSN[NA];CHRNG[NA];CHRNB1[NA];CACNA1A[0.246];ATXN7[0.012];APP[0.993];PDIA3[0.010];PHIP[NA];COL18A1[NA];FOXC1[NA];ZNF646[NA];GPC4[NA];DAXX[NA];HTATSF1[NA];RCN2[NA];XRCC6[NA];MDC1[NA];RSL1D1[NA];MAP1B[NA];MKI67[NA];LIG3[NA];H1FX[NA];MCM2[NA];RBBP7[NA];UBN1[NA];CTCF[NA];CCAR2[NA];RAI1[NA];ZMYM2[NA];C5orf24[NA];NUMA1[NA];MCM4[NA];HIST1H1C[NA];UCHL1[NA];PHF14[NA];ZNF428[NA];ZNF711[NA];TEX10[NA];LAS1L[NA];NR2F2[NA];RREB1[NA];BAZ1A[NA];YWHAH[NA];SATB1[NA];MBD1[NA];DDB1[NA];SDC1[NA];SRRM2[NA];TFAP2A[NA];DCAF1[NA];MGA[NA];GTPBP4[NA];USP7[NA];HIST1H1E[NA];PARP1[NA];UBN2[NA];RFX1[NA];ZNF148[NA];H2AFY2[NA];BAZ2A[NA];NBN[NA];COPA[NA];DNAJC9[NA];YWHAG[NA];ZMYM4[NA];TWNK[NA];HIRA[NA];SENP3[NA];HIST1H4A[NA];ZNF384[NA];LAMB1[NA];PPM1G[NA];NR2C2[NA];HSPG2[NA];PELP1[NA];XRCC5[NA];SUPT5H[NA];SDC2[NA];CHD4[NA];SAFB2[NA];TMPO[NA];NCOA5[NA];RNH1[NA];DNAJC7[NA];SMARCA1[NA];TTF2[NA];ATRX[NA];SUPT16H[NA];PYHIN1[NA];TFAM[NA];CBX5[NA];PARP2[NA];BAZ1B[NA];SAFB[NA];C1QBP[NA];SATB2[NA];MECP2[NA];TBP[NA];HOXA13[NA];RSF1[NA];ATP6V1B2[NA];RAD50[NA];CABIN1[NA];U2AF1[NA];SMARCA5[NA];NSUN2[NA];LAMC1[NA];TCF20[NA];ATIC[NA];PGK1[NA];HMBOX1[NA];HUWE1[NA];ATN1[0.011];GFI1B[0.012];TUBG1[0.016];ZFP41[0.009];SKI[0.210];CAMKV[0.007];CRP[0.999];OS9[0.057];OLFM3[0.999];UBC[0.109]; 37.11; 3.27; -0.6; 0.526344703; 29.49
136	LoF-FDR_ExAC	dbNSFP	4.0c	LoF-FDR (ExAC)	N		N	A gene's corresponding FDR p-value for preferential LoF depletion among the ExAC population. Lower FDR corresponds with genes that are increasingly depleted of LoF variants.	0.9905209; 0.3568659; 0.3751482; N; 0.9993496; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency; 0.40227; 0.4954952; 99.4; 0.9778728
137	RVIS_ExAC	dbNSFP	4.0c	RVIS(ExAC)	Y		N	ExAC-based RVIS; setting 'common' MAF filter at 0.05% in at least one of the six individual ethnic strata from ExAC.	2.274410941; 0.04; -1.365209057; 0.546707473; Disease-causing germline mutation(s) in; 0.636561334133148; 0.6738169; 1.24272779; 0.6528768; 26.23
138	RVIS_percentile_ExAC	dbNSFP	4.0c	RVIS(ExAC) percentile	Y		N	Genome-Wide percentile for the new ExAC-based RVIS; setting 'common' MAF filter at 0.05% in at least one of the six individual ethnic strata from ExAC.	98.9036805; 56.27; 4.843081742; 0.09620; Blood protein levels; Y; -0.175667739; 94.1569785; 0.6573556; 0.500554195
139	ExAC_pLI	dbNSFP	4.0c	pLI (ExAC)	N		N	the probability of being loss-of-function intolerant (intolerant of both heterozygous and homozygous lof variants) based on ExAC r0.3 data	0.176329298172162; 1.35381157129201e-10; 0.6597935; 2.51676266070248e-07; 0.00014794288110518; viral process;modification-dependent protein catabolic process;translesion synthesis;positive regulation of bone mineralization;negative regulation of protein ubiquitination;ISG15-protein conjugation;negative regulation of type I interferon production;regulation of interferon-gamma production;response to type I interferon;defense response to bacterium;negative regulation of viral genome replication;positive regulation of erythrocyte differentiation;defense response to virus;type I interferon signaling pathway; 0.573494831; 0.0908776364218918; 38.31696886; 8.36589277636991e-07
140	ExAC_pRec	dbNSFP	4.0c	pRec (ExAC)	N		N	the probability of being intolerant of homozygous, but not heterozygous lof variants based on ExAC r0.3 data	0.644086264144236; 0.18370000637236; 0.231569638; 0.722913600252338; 0.9; 0.245981533859779; extracellular region;nucleoplasm;cytosol; 0.64499; 0.765691410287669; 1.94738806982348e-05
141	ExAC_pNull	dbNSFP	4.0c	pNull (ExAC)	N		N	the probability of being tolerant of both heterozygous and homozygous lof variants based on ExAC r0.3 data	0.179584437683602; 0.816299993492259; 65.47195952; 0.277086148071396; 89.33; 0.753870523259116; protein binding;protein tag; 0.143430953290439; 0.46328044912402; 0.910002719700526
142	ExAC_nonTCGA_pLI	dbNSFP	4.0c	pLI (ExAC nonTCGA)	N		N	the probability of being loss-of-function intolerant (intolerant of both heterozygous and homozygous lof variants) based on ExAC r0.3 nonTCGA subset	0.550302420215064; 3.87526200981969e-10; 1.33038194561114e-19; 4.71815672240551e-06; 0.1809803; 0.000129277219206069; Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease. {ECO:0000269; -0.22; 0.338519010089551; 0.536700076995282
143	ExAC_nonTCGA_pRec	dbNSFP	4.0c	pRec (ExAC nonTCGA)	N		N	the probability of being intolerant of homozygous, but not heterozygous lof variants based on ExAC r0.3 nonTCGA subset	0.39663970580189; 0.177866269557236; 0.0025628417280481; 0.850701626623057; 1.879999506; 0.229411510944876; PubMed:22859821, ECO:0000269; 37.33; 0.601909186208019; 9.62326935096604e-05
144	ExAC_nonTCGA_pNull	dbNSFP	4.0c	pNull (ExAC nonTCGA)	N		N	the probability of being tolerant of both heterozygous and homozygous lof variants based on ExAC r0.3 nonTCGA subset	0.0530578739830465; 0.822133730055238; 0.997437158271952; 0.149293655220221; 97.96397807; 0.770459211835918; PubMed:7490683}.; 4.90286E-06; 0.05957180370243; 0.565670299146937
145	ExAC_nonpsych_pLI	dbNSFP	4.0c	pLI (ExAC nonpsych)	N		N	the probability of being loss-of-function intolerant (intolerant of both heterozygous and homozygous lof variants) based on ExAC r0.3 nonpsych subset	0.179613130021276; 2.28931804207666e-08; 1.95434996883495e-19; 6.50733790988587e-07; 2.01974835522321e-08; 0.00890752979462469; 0.70374788; 0.0833297729176883; 0.434233468159553; 5.98902171815392e-06
146	ExAC_nonpsych_pRec	dbNSFP	4.0c	pRec (ExAC nonpsych)	N		N	the probability of being intolerant of homozygous, but not heterozygous lof variants based on ExAC r0.3 nonpsych subset	0.623408532464667; 0.42248722639092; 0.00167039389288093; 0.659119875314906; 0.659994782009553; 0.549074235627792; 85.01897476; 0.736478134286935; 8.77227114766998e-05; 0.134560052127547
147	ExAC_nonpsych_pNull	dbNSFP	4.0c	pNull (ExAC nonpsych)	N		N	the probability of being tolerant of both heterozygous and homozygous lof variants based on ExAC r0.3 nonpsych subset	0.196978337514057; 0.5775127507159; 0.998329606107119; 0.340879473951303; 0.340005197792964; 0.442018234577583; UBA7[16189514;25416956;unassigned1304;17597759];ATL3[26259872];RPN2[26259872];PRKDC[26259872];TECR[26259872];SLC1A5[26259872];MAGT1[26259872];USP18[16189514;25416956;unassigned1304;25307056];RTN4[26259872];FSTL4[26259872];SEC61A1[26259872];EBP[26259872];SMPD4[26259872];TMEM43[26259872];NARS2[26259872];ARL6IP5[26259872];FLNB[19270716];QSOX2[26259872];KCNN4[26259872];BCAP31[26259872];SACM1L[26259872];SURF4[26259872];DHCR24[26259872];NFKB1[25609649];SLC4A7[26259872];PPM1B[16872604];ELF3[17353931];REEP5[26259872];DAD1[26259872];NEDD4[18305167];OSTC[26259872];STT3B[26259872];DHCR7[26259872];CLPTM1L[26259872];SEC22B[26259872];ERGIC3[26259872];ERGIC1[26259872]; 0.17335234048116; 0.180192092795376; 0.51582495828253
148	gnomAD_pLI	dbNSFP	4.0c	pLI (gnomAD)	N		N	the probability of being loss-of-function intolerant (intolerant of both heterozygous and homozygous lof variants) based on gnomAD 2.1 data	3.0650e-02; 1.3168e-02; 2.5957e-07; 1.42787593106998e-16; 1.1416e-16; 5.57433430125823e-08; 2.5764e-02; UBE2D3[17719635];IFIT5[16009940];HNRNPU[16009940];PLOD3[16009940];UBE2L6[16009940];ENO1[16884686;16009940;16815975];PLOD1[16009940];IFIT1[16009940];IFIT3[16009940];IFIT2[16009940];HERC5[16009940;16815975;24693865];RGS3[16884686];CFL1[16009940;16815975];PLS3[16009940];TRIM25[17222803];UBAP2L[16009940];CCNL1[16009940];PLS1[16009940];DDX17[16009940];ACOT8[16009940];IFNA14[26186194;28514442];CSNK2A1[16009940];ACTN1[16009940];TMOD3[16009940];ZNF281[16009940];DYRK1A[16009940];ARID5B[16009940];ACTN4[16009940];PGD[16009940];QTRTD1[16009940];ATXN2L[16009940];ACLY[16009940];CIRH1A[16009940];EEF1A2[16009940];ZNF318[22939629];RPL24[16009940];LAP3[16009940];SNRNP200[16009940];PFN1[16009940];EZR[16009940];SQSTM1[25429107];CFTR[26618866];IFNA10[28514442];VCP[16009940];UBA7[16189514;16884686;16009940;22693631;14976209;20975683;25416956];YTHDC1[16009940];MEPCE[16009940];TARS[16009940];IQGAP1[16009940];ZC3HAV1[16009940];AAAS[16009940];FUT4[16884686];HELZ2[16009940];ATP5B[16009940];ATXN2[16009940];LDHA[16009940];CALD1[16009940];RDH11[16009940];BAG3[23824909];PRDX1[16009940;16815975];STK38[16884686];G3BP1[16009940];PGK1[16009940];SFN[17222803];MAP4[16009940];ZC3H15[16009940];IFNA21[28514442];HSPA8[16009940;16815975];XRCC6[16009940];SMAD4[16009940];CBX4[16009940];HSPA4[16884686];XRCC5[16009940];TNK2[28514442];MSN[16009940];EIF2AK2[16009940];DSTN[16815975];EEF2[16009940];PRDX6[16815975];GNB2L1[16009940];IFNW1[28514442];CLK1[16009940];HNRNPL[16009940];HNRNPK[16009940];FUBP3[16009940];NACA[16009940];FASN[16009940];RPL27A[16009940];OGDH[16009940];EIF4G1[16009940];LGMN[16009940];TOP2A[16009940];IFNA5[26186194;28514442];GPI[16009940];IFNA4[28514442];HSP90AB1[16009940];WDR1[16009940];IFNA1[28514442];PPP1R10[16009940];CLTC[16009940];GDI2[16009940];IFNA2[26186194;28514442];DDX42[16009940];HSPB1[16815975];CHD1[16009940];ELAVL1[16009940];IFNA8[26186194;28514442];FARS2[16009940];PTBP1[16009940];ATIC[16009940];SIN3A[16009940];PHGDH[16009940];CLIC1[16009940];CCT3[16009940];CCT2[16009940];HSP90AA1[16009940];WARS[16009940];ANXA2[16009940];ANXA3[16009940];DDX58[16009940];ANXA5[16009940];MYOF[16009940];SEPT2[18305167];SERPINB5[16009940];DDB2[16009940];SENP1[16009940];WDR33[16009940];EEF1G[16009940];ACTA1[16009940];PPM1B[16884686];DEPDC7[16009940];PKM[16009940];ELF3[17353931];PALLD[16009940];MYH9[16009940];ALDOA[16009940];TKT[16009940];GAPDH[16815975];CHMP5[20164219;16009940];PAFAH1B1[16009940];PLEC[16009940];WIBG[16009940];SF3B4[16009940];TAGLN[16009940];NFIX[16009940];AHNAK[16009940];GSTP1[16009940];ATP5A1[16009940];USP18[16189514;25307056;25416956];PSMA7[16009940];HDAC6[25429107];HSPD1[16009940];DNAJB1[16009940];RBM15B[16009940];GANAB[16009940];UGP2[22939629];RBBP4[16009940];FAM120C[16009940];DNAJB4[16009940];LMAN2[16009940];LMNA[16009940];FLNA[16009940];FLNB[16009940];NUP43[16009940];ABCF2[16009940];RPS27A[16009940];GBP1[16009940];IFNL3[28514442];CCT4[16009940];SF3A2[16009940];YTHDF3[16009940];STAT1[16009940];USP21[21399617];TXNRD1[16009940];GSR[16009940];MX1[16009940];NEDD4[18287095];ERCC2[16884686];HNRNPA2B1[16009940];SERBP1[16009940];CTNNB1[20581239];EPPK1[16009940];VIM[16009940];TAF2[16009940];RAN[16009940];HSPA1A[16009940]; 0.826647657926747; 2.5897e-02
149	gnomAD_pRec	dbNSFP	4.0c	pRec (gnomAD)	N		N	the probability of being intolerant of homozygous, but not heterozygous lof variants based on gnomAD 2.1 data	6.1116e-01; 6.7560e-01; 3.0148e-01; 0.0104452108536494; 1.9831e-02; 0.639081791583738; 5.7614e-01; UBA7[0.999];NEDD4[0.943];UBE2L6[0.999];PPM1B[0.979];FLNB[0.930];IRF3[0.993];PCNA[0.608];XRCC6[0.567];IRF9[0.985];EZR[0.192];CSNK2A1[0.533];SMAD4[0.527];PLOD1[0.984];HNRNPK[0.153];ANXA5[0.878];EIF2AK2[0.989];WDR33[0.986];AHNAK[0.098];ATXN2L[0.005];DDX17[0.411];SERPINB5[0.998];TXNRD1[0.644];TOP2A[0.174];EEF1G[0.822];DDB2[0.318];EEF1A2[0.215];TMOD3[0.113];PGD[0.847];CALD1[0.331];CREBBP[NA];IRF3[NA];VCP[0.966];PSMA7[0.584];RACK1[0.127];ACTN4[0.793];PPP1R10[0.033];UBAP2L[0.087];LMNA[0.164];ARID5B[0.032];STAT1[NA];STAT2[NA];IRF9[NA];EP300[0.723];IRF4[0.980];PLOD3[0.204];HNRNPU[0.178];MX1[0.993];IRF1[NA];IRF9[NA];IFIT3[0.005];PLS1[0.532];STAT1[0.967];RPL27A[0.922];UBE2N[0.969];PTBP1[0.047];PFN1[0.081];IRF8[0.992];IRF7[0.979];IFIT1[0.994];G3BP1[0.637];ENO1[0.892];TKT[0.657];DYRK1A[0.041];HSP90AB1[0.988];VIM[0.514];LAP3[0.186];CLIC1[0.040];RELA[0.984];CBX4[0.201];PAFAH1B1[0.219];NUP43[0.419];IRF1[0.987];RAN[0.595];CLTC[0.968];IQGAP1[0.415];FUBP3[0.108];UTP4[0.029];FLNA[0.954];ALDOA[0.999];EIF4G1[0.990];HNRNPL[0.106];PLEC[0.258];OGDH[0.402];FASN[0.759];IFIT5[0.004];ACLY[0.921];YTHDC1[0.036];SIN3A[0.071];HSPD1[0.961];ZNF281[0.038];CCT4[0.858];GSTP1[0.890];MYH9[0.232];STAT1[NA];STAT2[NA];MYNN[0.029];SNRNP200[0.046];LGMN[0.771];CCNL1[0.032];CLK1[0.114];FARS2[0.247];HSPA8[0.965];HSP90AA1[0.965];FAM120C[0.004];SF3B4[0.044];CHMP5[0.631];ACOT8[0.410];MSN[0.069];TARS[0.780];ANXA3[0.118];SERBP1[0.174];EEF2[0.968];ANXA2[0.983];ACTA1[0.692];ATIC[0.880];DNAJB1[0.117];RDH11[0.118];MED14[0.048];GPI[0.999];LDHA[0.876];SF3A2[0.056];SENP1[0.127];IRF2[0.953];PRDX1[0.369];CFL1[0.558];CCT3[0.650];DDX58[0.996];RPS27A[0.982];HSPA1A[0.940];LMAN2[0.315];MAP4[0.103];TAGLN[0.579];RPL24[0.960];PYM1[0.101];CCT2[0.985];ACTN1[0.758];CREBBP[0.707];WARS[0.740];ATXN2[0.346];TAF2[0.043];WDR1[0.995];ELAVL1[0.672];GDI2[0.887];PKM[0.938];STAT1[NA];IRF9[NA];ABCF2[0.170];ZC3H15[0.173];PHGDH[0.999];RBBP4[0.063];ATP5F1A[0.418];SPI1[0.353];EPPK1[0.099];GSR[0.738];AAAS[0.182];IRF1[NA];IRF2[NA];HNRNPA2B1[0.129];CHD1[0.106];MYOF[0.122];GANAB[0.506];DDX42[0.101];HERC5[0.997];USP18[0.992];RTN4[NA];MAGT1[NA];ELF3[0.250];HSPA1L[NA];HNRNPK[NA];PIP[NA];HIST1H2AA[NA];SFXN1[NA];HIST1H1B[NA];ALOX12B[NA];HSPD1[NA];CHD3[NA];RPS3[NA];FBL[NA];AZGP1[NA];NFKB1[NA];LRRIQ4[NA];TRIM72[NA];TUBA4A[NA];HSPA8[NA];ALDH5A1[NA];VARS[NA];GAPDH[NA];ACTBL2[NA];TUFM[NA];MSH2[NA];UQCRC2[NA];RPS18[NA];PSMC2[NA];RAN[NA];PRKDC[NA];DIRAS2[NA];ACTA2[NA];HSPA9[NA];TARDBP[NA];HIST1H1C[NA];APRT[NA];HK1[NA];MRPS31[NA];BLMH[NA];PRSS1[NA];RIF1[NA];HSP90AB1[NA];ALPI[NA];CDK1[NA];HNRNPH1[NA];SLC1A5[NA];NSDHL[NA];LRPPRC[NA];RPS14[NA];VIM[NA];HNRNPA2B1[NA];ACTB[NA];EEF1A1[NA];PRSS3[NA];PDHB[NA];TUBB4A[NA];TUBB4B[NA];A2ML1[NA];PARP1[NA];INA[NA];AIFM1[NA];C4orf19[NA];ATP5F1A[NA];SLC25A12[NA];LMNB1[NA];FRMD8[NA];ELAVL1[NA];PRPH[NA];MTHFD1[NA];HIST1H2BB[NA];KPNA2[NA];RUVBL2[NA];SLC25A13[NA];VTN[NA];EIF4A1[NA];SYNCRIP[NA];FKBP8[NA];RBMX[NA];PRDX1[NA];CDSN[NA];SSR1[NA];REL[NA];ANKRD24[NA];RPS16[NA];TUBB1[NA];DDX21[NA];IGF2BP1[NA];RPS15A[NA];TUBB2A[NA];CAT[NA];HSPA6[NA];RPS10P5[NA];NAV3[NA];CEP112[NA];HIST1H1A[NA];GGCT[NA];GNAS[NA];RPS3A[NA];TUBB3[NA];HIST1H2BC[NA];STXBP4[NA];OAT[NA];HSP90AB2P[NA];HOXC8[NA];HNRNPU[NA];CCT3[NA];ATP5F1B[NA];HPF1[NA];HIST1H4A[NA];PFKP[NA];RUVBL1[NA];HIST1H2AB[NA];MAP3K8[NA];TUBG1[NA];SEMG2[NA];ANXA2[NA];CKAP5[NA];SEMG1[NA];RELA[NA];COPB2[NA];HNRNPM[NA];IGKC[NA];HIST1H2BA[NA];BSG[NA];PSMC3[NA];TFAM[NA];SLC25A5[NA];PSMD2[NA];EEF1G[NA];TTF2[NA];SLC25A4[NA];RPS4X[NA];H1F0[NA];CFAP73[NA];DBT[NA];RPS10[NA];EEF1D[NA];TUBB[NA];JCHAIN[NA];NFKB2[NA];RPL11[NA];ETFA[NA];NPEPPS[NA];SBSN[NA];DDX17[NA];FARSA[NA];HSPA2[NA];SNRPB[NA];ATP1A1[NA];PKM[NA];PRDX2[NA];NSUN2[NA];IRS4[NA];TOMM22[NA];DDX39A[NA];TNIP2[NA];HSPA5[NA];TMEM43[NA];SLC1A5[NA];KCNN4[NA];ATL3[NA];DHCR7[NA];QSOX2[NA];TECR[NA];MAGT1[NA];STT3B[NA];RTN4[NA];DHCR24[NA];BCAP31[NA];SEC22B[NA];SMPD4[NA];OSTC[NA];FSTL4[NA];PRKDC[NA];ARL6IP5[NA];SEC61A1[NA];REEP5[NA];ERGIC3[NA];SLC4A7[NA];RPN2[NA];DAD1[NA];EBP[NA];SACM1L[NA];SURF4[NA];ERGIC1[NA];CLPTM1L[NA];NARS2[NA];PPM1B[NA];IFNB1[NA];PPM1B[NA];UBA7[NA];UBE2E2[NA];SEPT2[0.124];UBE2D3[0.984];RGS3[0.676];ERCC2[0.531];HSPA4[0.808];STK38[0.096];FUT4[0.075];ATP5F1B[0.422];YTHDF3[0.004];RBM15B[0.035];DNAJB4[0.111];MEPCE[0.006];GBP1[0.967];IFIT2[0.115];DEPDC7[0.004];PALLD[0.089];NFIX[0.033];PGK1[0.876];PLS3[0.547];HELZ2[0.033];QTRT2[0.295];XRCC5[0.583];ZC3HAV1[0.162];TRIM25[0.993];SFN[0.996];USP21[0.007];DSTN[0.208];GAPDH[0.661];HSPB1[0.459];PRDX6[0.988];CTNNB1[0.643];UGP2[0.730];ZNF318[0.111];BAG3[0.606];HDAC6[0.466];SQSTM1[0.972];IFNA14[0.999];IFNA2[0.999];IFNA5[0.999];IFNA8[0.999];IFNW1[0.999];IFNA1[0.999];IFNA21[0.999];TNK2[0.191];IFNA10[0.999];IFNA4[0.999];IFNL3[0.999]; 1.59209302093807e-09; 5.7719e-01
150	gnomAD_pNull	dbNSFP	4.0c	pNull (gnomAD)	N		N	the probability of being tolerant of both heterozygous and homozygous lof variants based on gnomAD 2.1 data	3.5819e-01; 3.1123e-01; 6.9852e-01; 0.98955478914635; 9.8017e-01; 0.360918152672919; 3.9809e-01; 0.10000; 0.0403025247483816; 3.9692e-01
151	ExAC_del.score	dbNSFP	4.0c	Deletion intolerance z-core	Y		N	Winsorised deletion intolerance z-score based on ExAC r0.3.1 CNV data	-1.30231557829469; 2.6426e-29; -1.85618066193215; 2.94867415806838e-07; -0.854090636010466; 0.460647642612457; 0.95969745668599; 6.4810e-01; -0.411262678743063; 7.9971e-01
152	ExAC_dup.score	dbNSFP	4.0c	Duplication intolerance z-score	Y		N	Winsorised duplication intolerance z-score based on ExAC r0.3.1 CNV data	-2.53125239294469; 4.9621e-05; 0.727056610292468; -1.63096181793128; N; 1.85656278974184e-08; -0.107338132620471; -0.879111583779016; 1.9944e-01; -0.0672591593714552
153	ExAC_cnv.score	dbNSFP	4.0c	CNV intolerance z-score	Y		N	Winsorised cnv intolerance z-score based on ExAC r0.3.1 CNV data	-2.47162789907313; 9.9995e-01; 0.272943094840116; -1.53319165737073; 0.510442854; 0.432276824423558; -1.547525137109; -0.823164297355822; -1.38938551075959; 7.6706e-01
154	ExAC_cnv_flag	dbNSFP	4.0c	CNV flag	Y		N	Gene is in a known region of recurrent CNVs mediated by tandem segmental duplications and intolerance scores are more likely to be biased or noisy from ExAC r0.3.1 CNV release	N; -1.28066949641572; 1.8027e-03; 0.22633; 0.56772317046328; -1.22537295612016; -1.07852675058797; 2.1157e-01; -0.394193176188832; -1.22487190884017
155	GDI	dbNSFP	4.0c	Gene damage index (GDI)	Y		N	gene damage index score, a genome-wide, gene-level metric of the mutational damage that has accumulated in the general population from doi: 10.1073/pnas.1518646112. The higher the score the less likely the gene is to be responsible for monogenic diseases.	113.16669; 835.24604; -2.53125239294469; 60.97395; 7.3042e-01; 1800.58057; 5.11316184674638e-09; 350.3187; 56.85253; N
156	GDI-Phred	dbNSFP	4.0c	GDI phred score	Y		N	Phred-scaled GDI scores	2.31572; 5.65821; -2.31189826471188; 1.58809; 2.6777e-01; 7.82660; -0.12; 1.0785e-01; 3.96842; 1.51792
157	GDP	dbNSFP	4.0c	Gene damage prediction (all disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for all diseases	Medium; N; -2.54252356721664; 45.13; 8.8620e-01; 10.12799; 28.93778; 2.26829; 103.46629; 880.06096
158	GDP_mendelian	dbNSFP	4.0c	Gene damage prediction (all Mendelian disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for all Mendelian diseases	Medium; 783.46189; -2.25597869426552; 0.8494748; 5.9548e-03; 0.92448; 2.19737; 5.77750; N; 4.39394
159	GDP_mendelian_AD	dbNSFP	4.0c	Gene damage prediction (Mendelian AD disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for Mendelian autosomal dominant diseases	Medium; 5.53337; -2.3252444322095; 0.410434686; -0.195411282716471; 720.15343; 763.45124; 16.40046; 0.01602; Low
160	GDP_mendelian_AR	dbNSFP	4.0c	Gene damage prediction (Mendelian AR disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for Mendelian autosomal recessive diseases	Medium; N; 74.54370219; -0.871382761831082; 5.32791; 5.47580; High; 1511.84536; Low; 16.15546
161	GDP_PID	dbNSFP	4.0c	Gene damage prediction (all PID disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for all primary immunodeficiency diseases	Medium; 709.4528; 0.00984781293610986; -0.676226119735614; High; 7.22185; Low; 147.53387; N; 3.89213
162	GDP_PID_AD	dbNSFP	4.0c	Gene damage prediction (PID AD disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for primary immunodeficiency autosomal dominant diseases	Medium; 5.29021; 0.600249312746062; N; High; Low; 2.64628; 63.44396; -1.19749535995947; 0.641174429873505
163	GDP_PID_AR	dbNSFP	4.0c	Gene damage prediction (PID AR disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for primary immunodeficiency autosomal recessive diseases	Medium; 0.389902874317828; 1338.6014; High; Low; 1.63119; N; 2.6323e-28; 2.77476; 9.87912
164	GDP_cancer	dbNSFP	4.0c	Gene damage prediction (all cancer disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for all cancer disease	Medium; 0.00889061739074356; 6.86990; High; Low; 1261.89174; 3.6025e-02; 5.33625; PubMed:9070310}.; 3.7815e-01
165	GDP_cancer_rec	dbNSFP	4.0c	Gene damage prediction (cancer recessive disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for cancer recessive disease	Medium; 0.578754997482166; High; Low; 6.69837; 9.6398e-01; pharynx;stomach;testis;pineal gland;choroid;kidney;uterus;whole body;pancreas;adrenal gland;trophoblast;islets of Langerhans;visual apparatus;iris;vein;liver;germinal center;heart;lung;salivary gland;thyroid;sympathetic chain;placenta;nasopharynx;optic nerve;intestine;tongue;skin;pituitary gland;adrenal cortex;lens;lymphoreticular;unclassifiable (Anatomical System);retina;head and neck;mammary gland;umbilical cord;tonsil;cervix;hippocampus;endometrium;bone;parathyroid;brain;blood;bone marrow;ovary;lymph node;bladder;frontal lobe;colon;prostate;breast;hypothalamus;medulla oblongata; 7.4245e-03; 0.34; -0.0248062312728537
166	GDP_cancer_dom	dbNSFP	4.0c	Gene damage prediction (cancer dominant disease-causing genes)	Y		N	gene damage prediction (low/medium/high) by GDI for cancer dominant disease	Medium; 0.41235438512709; High; Low; 0.458012077584659; caudate nucleus;olfactory bulb;temporal lobe;prefrontal cortex;cingulate cortex;pons;kidney;adrenal gland;spinal cord;parietal lobe;medulla oblongata;hypothalamus;thalamus; 0.726876409273004; 1.27676E-13; 0.854953981725245; 11.29956
167	LoFtool_score	dbNSFP	4.0c	LoF	Y		N	a percentile score for gene intolerance to functional change. The lower the score the higher gene intolerance to functional change. For details see doi: 10.1093/bioinformatics/btv602.	Medium; 3.86E-01; 0.0584431202198305; 2.93E-01; 4.71E-01; 7.88E-01; 4.21E-01; 4.41E-01; High; Low
168	SORVA_LOF_MAF0.005_HetOrHom	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Heterozygote or Homozygote of LOF SNVs whose MAF<0.005. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; 3.9936102236421724E-4; 0.0023961661341853034; Medium; 7.987220447284345E-4; 0.687740607257902; 9.50E-01; 5.85E-01; 0.003594249201277955; 0.003194888178913738
169	SORVA_LOF_MAF0.005_HomOrCompoundHet	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Compound Heterozygote or Homozygote of LOF SNVs whose MAF<0.005. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; Medium; 0.253816272522267; 0.003993610223642172; 3.9936102236421724E-4; 3.04E-01; 8.40E-01; 4.30E-01; High; Low
170	SORVA_LOF_MAF0.001_HetOrHom	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Heterozygote or Homozygote of LOF SNVs whose MAF<0.001. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; 3.9936102236421724E-4; 0.0023961661341853034; 8.87E-01; Medium; 0.00439297124600639; 7.987220447284345E-4; 3.9557e-01; 0.006789137380191693; 0.009584664536741214
171	SORVA_LOF_MAF0.001_HomOrCompoundHet	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Compound Heterozygote or Homozygote of LOF SNVs whose MAF<0.001. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; 0.001597444089456869; Medium; 4.8061e-01; 0.003993610223642172; 3.9936102236421724E-4; 6.34E-01; 7.987220447284345E-4; 0.0023961661341853034; 0.0011980830670926517
172	SORVA_LOForMissense_MAF0.005_HetOrHom	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Heterozygote or Homozygote of LOF or missense SNVs whose MAF<0.005. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; 0.022763578274760384; 0.0762779552715655; 0.024361022364217253; Medium; 0.001597444089456869; 0.03274760383386582; 1.2383e-01; 0.034345047923322686; 0.027955271565495207
173	SORVA_LOForMissense_MAF0.005_HomOrCompoundHet	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Compound Heterozygote or Homozygote of LOF or missense SNVs whose MAF<0.005. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; 0.00439297124600639; 0.0059904153354632585; 0.001597444089456869; 7.987220447284345E-4; 9.26E-01; 0.003194888178913738; -0.655956146050992; Medium; 0.07587859424920128
174	SORVA_LOForMissense_MAF0.001_HetOrHom	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Heterozygote or Homozygote of LOF or missense SNVs whose MAF<0.001. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; 0.008386581469648562; 0.036741214057507986; 0.019169329073482427; 0.0011980830670926517; 0.05151757188498403; 0.010782747603833865; -1.66066626021856; Medium; 0.013178913738019169
175	SORVA_LOForMissense_MAF0.001_HomOrCompoundHet	dbNSFP	4.0c		N		N	the fraction of individuals in the 1000 Genomes Project data (N=2504) who are either Compound Heterozygote or Homozygote of LOF or missense SNVs whose MAF<0.001. This fraction is from a method for ranking genes based on mutational burden called SORVA (Significance Of Rare VAriants). Please see doi: 10.1101/103218 for details.	0.0; 0.001996805111821086; 0.001597444089456869; 0.06589456869009584; 7.987220447284345E-4; 3.9936102236421724E-4; -1.45000690532075; 4.21E-01; 0.041932907348242815; 0.011182108626198083
176	Essential_gene	dbNSFP	4.0c	Essential gene (MGI)	N		N	Essential ('E') or Non-essential phenotype-changing ('N') based on Mouse Genome Informatics database. from doi:10.1371/journal.pgen.1003484	0.008386581469648562; 0.0011980830670926517; 0.03154952076677316; N; 0.0; 3.9936102236421724E-4; 0.00878594249201278; 0.017172523961661343; 0.011182108626198083; 0.0027955271565495207
177	Essential_gene_CRISPR	dbNSFP	4.0c	Essential gene (CRISPR)	N		N	Essential ('E') or Non-essential phenotype-changing ('N') based on large scale CRISPR experiments. from doi: 10.1126/science.aac7041	N; 0.04153354632587859; 0.0; 7.987220447284345E-4; 1374.86701; 3.9936102236421724E-4; E; 0.03154952076677316; 0.05910543130990415; 0.0011980830670926517
178	Essential_gene_CRISPR2	dbNSFP	4.0c	Essential gene (CRISPR2)	N		N	Essential ('E'), context-Specific essential ('S'), or Non-essential phenotype-changing ('N') based on large scale CRISPR experiments. from http://dx.doi.org/10.1016/j.cell.2015.11.015	N; 3.9936102236421724E-4; 0.0762779552715655; S; 6.95277; 0.0; 0.009584664536741214; 0.0115814696485623; E; 0.018370607028753993
179	Essential_gene_gene-trap	dbNSFP	4.0c	Essential gene (gene-trap)	N		N	Essential ('E'), HAP1-Specific essential ('H'), KBM7-Specific essential ('K'), or Non-essential phenotype-changing ('N'), based on large scale mutagenesis experiments. from doi: 10.1126/science.aac7557	N; 0.005191693290734824; Medium; 0.0; E; 0.02156549520766773; 7.987220447284345E-4; 0.0011980830670926517; S; 0.009984025559105431
180	Gene_indispensability_score	dbNSFP	4.0c		N		N	A probability prediction of the gene being essential. From doi:10.1371/journal.pcbi.1002886	0.114371359811310; 0.000683535100850493; 0.187549044243291; E; 0.323193869751981; 0.03634185303514377; 0.99544852671045; Medium; 0.16853035143769968; N
181	Gene_indispensability_pred	dbNSFP	4.0c		N		N	Essential ('E') or loss-of-function tolerant ('N') based on Gene_indispensability_score.	N; E; 0.0023961661341853034; Medium; 0.017971246006389777; 0.0884618892570334; 0.92867963348666; H; 0.0208174400685481; 0.239335832271138
182	MGI_mouse_gene	dbNSFP	4.0c	Mouse gene (MGI)	N		N	Homolog mouse gene name from MGI	Olfr1303; Samd11; N; Klhl17; Medium; 0.07707667731629393; Rnf223; 9430015G10Rik; Tnfrsf18; 0.604344439678925
183	MGI_mouse_phenotype	dbNSFP	4.0c	Mouse phenotype (MGI)	N		N	Phenotype description for the homolog mouse gene from MGI	0.946496023965855; N; Medium; 0.00439297124600639; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); hematopoietic system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; Ttll10; hematopoietic system phenotype; cellular phenotype; immune system phenotype; E; Sdf4; growth/size/body region phenotype
184	ZFIN_zebrafish_gene	dbNSFP	4.0c	Zebrafish gene (ZFIN)	N		N	Homolog zebrafish gene name from ZFIN	E; N; Perm1; Medium; homeostasis/metabolism phenotype; Tnfrsf4; 0.736119820232014; C1qtnf12; Ube2j2; Ints11
185	ZFIN_zebrafish_structure	dbNSFP	4.0c	Zebrafish structure (ZFIN)	N		N	Affected structure of the homolog zebrafish gene from ZFIN	Noc2l; N; Medium; homeostasis/metabolism phenotype; cellular phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); immune system phenotype; digestive/alimentary phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; respiratory system phenotype; liver/biliary system phenotype; sdf4; E; taste/olfaction phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); Atad3a; 0.735489525488829
186	ZFIN_zebrafish_phenotype_quality	dbNSFP	4.0c	Zebrafish phenotype quality (ZFIN)	N		N	Phenotype description for the homolog zebrafish gene from ZFIN	endocrine/exocrine gland phenotype; cellular phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; immune system phenotype; 0.259498654175253; Medium; N; dorsal longitudinal anastomotic vessel; B3galt6; ints11; Cptp; Ccnl2; muscle phenotype; homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span)
187	ZFIN_zebrafish_phenotype_tag	dbNSFP	4.0c	Zebrafish phenotype tag (ZFIN)	N		N	Phenotype tag for the homolog zebrafish gene from ZFIN	noc2l; N; Medium; aplastic; hemopoiesis; Atad3a; decreased size; E; cellular phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); embryo phenotype; 0.97172769797035
188	gnomAD	gnomADmetrics	v2.1.1	gnomAD	Y	https://gnomad.broadinstitute.org/gene/<ID>	N	gnomAD gene	ENSG00000186092; ENSG00000187961; ENSG00000187583; ENSG00000187642; ENSG00000188290; ENSG00000187608; ENSG00000188157; ENSG00000237330; ENSG00000131591; ENSG00000162571
189	obs_mis	gnomADmetrics	v2.1.1	Observed missense	Y		N		67; 467; 480; 422; 103; 117; 1303; 124; 120; 387
190	exp_mis	gnomADmetrics	v2.1.1	Expected missense	Y		N		8.2715e+01; 4.3355e+02; 3.8117e+02; 3.9110e+02; 9.0430e+01; 1.1566e+02; 1.3261e+03; 1.0779e+02; 1.3748e+02; 4.0570e+02
191	oe_mis	gnomADmetrics	v2.1.1	o/e (missense)	Y		N		8.1001e-01; 1.0772e+00; 1.2593e+00; 1.0790e+00; 1.1390e+00; 1.0115e+00; 9.8257e-01; 1.1504e+00; 8.7288e-01; 9.5390e-01
192	mu_mis	gnomADmetrics	v2.1.1		N		N		4.1668e-06; 3.1317e-05; 2.4060e-05; 2.4195e-05; 4.1431e-06; 8.0856e-06; 9.9464e-05; 7.7410e-06; 9.6849e-06; 2.7128e-05
193	possible_mis	gnomADmetrics	v2.1.1		N		N		1978; 4083; 3802; 4345; 1473; 1057; 12779; 1522; 1242; 4295
194	obs_mis_pphen	gnomADmetrics	v2.1.1		N		N		29; 167; 135; 110; 30; 31; 342; 12; 28; 109
195	exp_mis_pphen	gnomADmetrics	v2.1.1		N		N		3.1909e+01; 1.7558e+02; 9.7727e+01; 9.7787e+01; 3.0382e+01; 3.1318e+01; 3.9487e+02; 2.1509e+01; 3.8432e+01; 1.1878e+02
196	oe_mis_pphen	gnomADmetrics	v2.1.1		N		N		9.0884e-01; 9.5114e-01; 1.3814e+00; 1.1249e+00; 9.8741e-01; 9.8985e-01; 8.6611e-01; 5.5790e-01; 7.2855e-01; 9.1763e-01
197	possible_mis_pphen	gnomADmetrics	v2.1.1		N		N		776; 1558; 1147; 1182; 389; 337; 3727; 407; 411; 1414
198	obs_syn	gnomADmetrics	v2.1.1	Observed synonymous	Y		N		28; 360; 216; 215; 53; 63; 727; 58; 72; 167
199	exp_syn	gnomADmetrics	v2.1.1	Expected synonymous	Y		N		3.0512e+01; 2.0109e+02; 1.7452e+02; 1.7481e+02; 4.1769e+01; 5.8149e+01; 6.0335e+02; 5.0639e+01; 6.5884e+01; 1.7460e+02
200	oe_syn	gnomADmetrics	v2.1.1	o/e (synonymous)	Y		N		9.1766e-01; 1.7903e+00; 1.2377e+00; 1.2299e+00; 1.2689e+00; 1.0834e+00; 1.2049e+00; 1.1454e+00; 1.0928e+00; 9.5647e-01
201	mu_syn	gnomADmetrics	v2.1.1		N		N		1.7760e-06; 1.6269e-05; 1.1429e-05; 1.2220e-05; 1.9868e-06; 4.4670e-06; 4.9630e-05; 3.7764e-06; 5.4986e-06; 1.2599e-05
202	possible_syn	gnomADmetrics	v2.1.1		N		N		607; 1359; 1323; 1611; 588; 363; 4373; 579; 413; 1367
203	obs_lof	gnomADmetrics	v2.1.1	Obsered LoF	Y		N		2; 26; 25; 21; 6; 0; 29; 7; 20; 8
204	exp_lof	gnomADmetrics	v2.1.1	Expected LoF	Y		N		2.3369e+00; 2.8650e+01; 3.1069e+01; 1.7757e+01; 3.5300e+00; 1.1056e+00; 9.0870e+01; 2.1002e+00; 1.0077e+01; 2.5676e+01
205	oe_lof	gnomADmetrics	v2.1.1	o/e (LoF)	Y		N		8.5584e-01; 9.0749e-01; 8.0467e-01; 1.1826e+00; 1.6997e+00; 0.0000e+00; 3.1914e-01; 9.5227e-01; 6.9466e-01; 7.7894e-01
206	mu_lof	gnomADmetrics	v2.1.1		N		N		9.6530e-08; 1.6488e-06; 1.5693e-06; 1.0314e-06; 1.5251e-07; 4.7048e-08; 5.0007e-06; 9.0400e-08; 5.1189e-07; 1.2353e-06
207	possible_lof	gnomADmetrics	v2.1.1		N		N		60; 292; 332; 204; 49; 12; 963; 38; 119; 293
208	pLI	gnomADmetrics	v2.1.1	pLI	Y		N	the probability of being loss-of-function intolerant (intolerant of both heterozygous and homozygous lof variants) based on gnomAD v2	3.0354e-02; 1.3052e-16; 1.1549e-14; 1.1667e-15; 1.3746e-05; 4.0527e-01; 5.4727e-07; 2.6565e-02; 1.6450e-04; 1.2286e-11
209	pNull	gnomADmetrics	v2.1.1	pNull	N		N		3.5740e-01; 9.7837e-01; 8.5111e-01; 9.9702e-01; 8.7001e-01; 1.1604e-01; 1.4068e-12; 3.8803e-01; 3.0053e-01; 6.8764e-01
210	pRec	gnomADmetrics	v2.1.1	pRec	N		N		6.1225e-01; 2.1625e-02; 1.4889e-01; 2.9832e-03; 1.2998e-01; 4.7870e-01; 1.0000e+00; 5.8541e-01; 6.9930e-01; 3.1236e-01
211	oe_syn_lower	gnomADmetrics	v2.1.1		N		N		6.7900e-01; 1.6410e+00; 1.1070e+00; 1.1000e+00; 1.0170e+00; 8.8400e-01; 1.1330e+00; 9.2600e-01; 9.0300e-01; 8.4200e-01
212	oe_syn_upper	gnomADmetrics	v2.1.1		N		N		1.2580e+00; 1.9390e+00; 1.3850e+00; 1.3770e+00; 1.5950e+00; 1.3360e+00; 1.2810e+00; 1.4250e+00; 1.3300e+00; 1.0870e+00
213	oe_mis_lower	gnomADmetrics	v2.1.1		N		N		6.6400e-01; 9.9800e-01; 1.1680e+00; 9.9600e-01; 9.7000e-01; 8.7000e-01; 9.3800e-01; 9.9400e-01; 7.5200e-01; 8.7700e-01
214	oe_mis_upper	gnomADmetrics	v2.1.1		N		N		9.9300e-01; 1.1630e+00; 1.3580e+00; 1.1690e+00; 1.3420e+00; 1.1790e+00; 1.0290e+00; 1.3350e+00; 1.0160e+00; 1.0380e+00
215	oe_lof_lower	gnomADmetrics	v2.1.1		N		N		3.2500e-01; 6.6400e-01; 5.8500e-01; 8.3700e-01; 8.1600e-01; 0.0000e+00; 2.3700e-01; 3.5200e-01; 3.9400e-01; 5.4700e-01
216	oe_lof_upper	gnomADmetrics	v2.1.1		N		N		1.8400e+00; 1.2590e+00; 1.1240e+00; 1.6860e+00; 1.9470e+00; 1.6910e+00; 4.3500e-01; 1.8670e+00; 1.3020e+00; 1.1320e+00
217	constraint_flag	gnomADmetrics	v2.1.1	Constraint flag (gnomAD)	Y		Y		syn_outlier; mis_too_many; no_exp_lof; no_variants; lof_too_many
218	syn_z	gnomADmetrics	v2.1.1	Z score (synonymous)	Y		N		3.5753e-01; -8.8090e+00; -2.4681e+00; -2.3898e+00; -1.3661e+00; -5.0008e-01; -3.9572e+00; -8.1312e-01; -5.9234e-01; 4.5219e-01
219	mis_z	gnomADmetrics	v2.1.1	Z score (missense)	Y		N		6.1403e-01; -5.7094e-01; -1.7988e+00; -5.5519e-01; -4.6973e-01; -4.4129e-02; 2.2552e-01; -5.5496e-01; 5.2966e-01; 3.2998e-01
220	lof_z	gnomADmetrics	v2.1.1	Z score (LoF)	Y		N		2.0421e-01; 4.5884e-01; 1.0089e+00; -7.1321e-01; -1.2182e+00; 9.7435e-01; 6.0143e+00; 6.4099e-02; 8.9818e-01; 1.0380e+00
221	oe_lof_upper_rank	gnomADmetrics	v2.1.1		N		N		17847; 13521; 12118; 16725; 18996; 16766; 4022; 18109; 13948; 12218
222	oe_lof_upper_bin	gnomADmetrics	v2.1.1		N		N		9; 7; 6; 8; 2; 4; 1; 3; 5; NA
223	oe_lof_upper_bin_6	gnomADmetrics	v2.1.1		N		N		5; 4; 3; 1; 2; NA; 0
224	n_sites	gnomADmetrics	v2.1.1		N		N		0; 33; 50; 8; 45; 7; 29; 9; 6; 16
225	classic_caf	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.4370e-04; 8.7804e-04; 1.8299e-04; 2.7434e-04; 3.4378e-05; 2.5172e-03; 1.2909e-04; 7.8657e-05; 8.4430e-05
226	max_af	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 5.2832e-05; 2.5184e-04; 7.2816e-05; 3.3964e-05; 9.3434e-06; 1.6688e-03; 4.0444e-05; 4.0506e-05; 1.6146e-05
227	no_lofs	gnomADmetrics	v2.1.1		N		N		0; 125310; 125455; 124573; 125566; 125216; 125180; 124996; 124534; 125703
228	obs_het_lof	gnomADmetrics	v2.1.1		N		N		0; 60; 177; 44; 64; 8; 562; 32; 19; 21
229	obs_hom_lof	gnomADmetrics	v2.1.1		N		N		0; 1; 5; 449; 4; NA; 7; 20; 49; 15
230	defined	gnomADmetrics	v2.1.1		N		N		0; 125370; 125633; 124617; 125630; 125224; 125747; 125028; 124553; 125724
231	p	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.3932e-04; 7.0866e-04; 1.7656e-04; 2.5475e-04; 3.1943e-05; 2.2571e-03; 1.2798e-04; 7.6276e-05; 8.3520e-05
232	exp_hom_lof	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 7.1805e-03; 6.3093e-02; 3.8846e-03; 8.1530e-03; 1.2778e-04; 6.4060e-01; 2.0478e-03; 7.2465e-04; 8.7699e-04
233	classic_caf_afr	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.7152e-03; 1.3773e-04; 2.5951e-04; 7.0349e-03; 5.6840e-04; 1.2817e-04; 6.1652e-05; 6.3865e-05; 3.3780e-03
234	classic_caf_amr	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.3435e-04; 2.0908e-04; 8.8595e-05; 4.5574e-04; 1.2367e-04; 7.6515e-04; 2.9097e-05; 2.9066e-05; 8.7492e-05
235	classic_caf_asj	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 1.0898e-04; 4.1102e-04; 1.0428e-04; 5.1493e-04; 2.0421e-04; 9.9681e-05; 2.6499e-02; 9.9305e-05; 1.9261e-03
236	classic_caf_eas	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.1891e-04; 2.8479e-04; 1.1039e-03; 1.6640e-04; 2.1430e-02; 5.4807e-05; 1.0928e-04; 2.7937e-04; 1.7663e-04
237	classic_caf_fin	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.7009e-04; 9.9890e-05; 1.9800e-04; 1.9082e-03; 3.6979e-04; 1.9856e-04; 9.7157e-05; 4.7170e-05; 1.0272e-01
238	classic_caf_nfe	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 3.7926e-04; 5.8498e-04; 1.1713e-04; 3.2021e-04; 1.7989e-05; 6.2696e-04; 9.8368e-05; 1.2922e-04; 9.8142e-05
239	classic_caf_oth	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 1.6426e-04; 7.3836e-04; 1.6892e-04; 2.8384e-03; 2.0438e-03; 1.6502e-04; 3.3763e-04; 1.3370e-03; 5.1692e-04
240	classic_caf_sas	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 1.6406e-04; 2.8601e-03; 2.3060e-04; 1.3681e-04; 3.2678e-05; 2.4477e-04; 2.9418e-04; 1.3084e-04; 3.9430e-04
241	p_afr	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.5889e-03; 1.2583e-04; 2.4631e-04; 6.3563e-03; 5.5909e-04; 1.2532e-04; 6.1533e-05; 6.2160e-05; 3.3593e-03
242	p_amr	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.3135e-04; 2.0239e-04; 8.7112e-05; 4.3377e-04; 1.1577e-04; 7.2297e-04; 2.8931e-05; 2.8984e-05; 8.6734e-05
243	p_asj	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 9.9369e-05; 3.9730e-04; 1.0003e-04; 4.9883e-04; 1.9962e-04; 9.9310e-05; 2.6543e-02; 9.9211e-05; 1.8867e-03
244	p_eas	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.1758e-04; 2.7189e-04; 1.0457e-03; 1.6318e-04; 1.9434e-02; 5.4414e-05; 1.0874e-04; 2.7204e-04; 1.6323e-04
245	p_fin	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 2.3099e-04; 9.2855e-05; 1.8483e-04; 1.8032e-03; 3.6962e-04; 1.8479e-04; 9.2392e-05; 4.6255e-05; 1.0182e-01
246	p_nfe	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 3.7124e-04; 5.1078e-04; 1.1556e-04; 2.9940e-04; 1.7709e-05; 5.0115e-04; 9.7642e-05; 1.2489e-04; 9.6725e-05
247	p_oth	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 1.6341e-04; 6.5253e-04; 1.6352e-04; 2.6093e-03; 1.9672e-03; 1.6368e-04; 3.2696e-04; 1.3042e-03; 4.8952e-04
248	p_sas	gnomADmetrics	v2.1.1		N		N		0.0000e+00; 1.6334e-04; 1.9944e-03; 2.2943e-04; 1.3067e-04; 3.2672e-05; 2.2866e-04; 2.9408e-04; 1.3066e-04; 3.5945e-04
249	transcript_level	gnomADmetrics	v2.1.1		N		N		2; 3; 1
250	cds_length	gnomADmetrics	v2.1.1	CDS length	Y		N		915; 1926; 1833; 2088; 741; 495; 6135; 747; 594; 2019
251	num_coding_exons	gnomADmetrics	v2.1.1	Number of coding exons	Y		N		1; 12; 16; 5; 3; 2; 36; 8; 13; 4
252	gene_type	gnomADmetrics	v2.1.1		N		N		protein_coding; polymorphic_pseudogene
253	gene_length	gnomADmetrics	v2.1.1		N		N		918; 5129; 9369; 6919; 1211; 1118; 35994; 3342; 34544; 24052
254	exac_pLI	gnomADmetrics	v2.1.1		N		N		1.7633e-01; 2.5168e-07; 2.0197e-08; NA; 1.4794e-04; 9.8478e-03; 1.7335e-01; 9.0878e-02; 1.9474e-05; 8.3659e-07
255	exac_obs_lof	gnomADmetrics	v2.1.1		N		N		1; 13; 15; NA; 5; 3; 2; 8; 4; 6
256	exac_exp_lof	gnomADmetrics	v2.1.1		N		N		2.2177e+00; 1.8832e+01; 2.1150e+01; NA; 3.4895e+00; 3.5107e+00; 5.4417e+01; 4.3923e+00; 9.6030e+00; 5.5684e+00
257	exac_oe_lof	gnomADmetrics	v2.1.1		N		N		4.5091e-01; 6.9030e-01; 7.0923e-01; NA; 1.4329e+00; 8.5454e-01; 2.3890e-01; 4.5534e-01; 8.3307e-01; 1.4367e+00
258	Marrvel	Marrvel	v1.2	marrvel	Y		N	Integrated information from six human genetic databases and seven model organism databases	DDX11L1; WASH7P; MIR6859-1; MIR1302-2HG; MIR1302-2; FAM138A; OR4G4P; OR4G11P; OR4F5; AL627309.1
259	s_het	CassaNatGenet2017	04/03/2017	s_het	Y		N		0.007702292; 0.005405258; 0.013762146; 0.006848947; 0.008602742; 0.02313541; 0.012195309; 0.021193902; 0.033507307; 0.01844127
260	enstid	GenCode	v33	ENSEMBL transcript ID	Y		N		ENST00000456328.2; ENST00000488147.1; ENST00000619216.1; ENST00000473358.1; ENST00000607096.1; ENST00000417324.1; ENST00000606857.1; ENST00000642116.1; ENST00000641515.2; ENST00000466430.5
261	enspid	GenCode	v33	ENSEMBL protein ID	Y		N		ENSP00000493376.2; ENSP00000409316.1; ENSP00000329982.2; ENSP00000411579.2; ENSP00000317992.6; ENSP00000343930.3; ENSP00000368720.3; ENSP00000343864.2; ENSP00000393198.2; ENSP00000485643.1
262	refseq	GenCode	v33	RefSeq ID	Y		N		NR_024005.3~NR_046018.2~NR_051986.1~NR_110561.1~NR_148357.1; NR_024540.1; NR_106918.1; NR_036051.1; NR_026818.1; NR_107062.1; NM_001005221.2; NM_001005277.1; NR_103536.1; NR_024321.1
263	refseq_protein	GenCode	v33	RefSeq Protein ID	Y		N		NP_001005221.2; NP_001005277.1; NP_056473.3; NP_938073.1; NP_001354481.1~NP_115505.2; NP_001278296.2; NP_001135939.1; NP_940978.2; NP_001192181.1; NP_001317235.1
264	pos	GenCode	v33		Y		N		11869-14409; 14404-29570; 17369-17436; 29554-31097; 30366-30503; 34554-36081; 52473-53312; 57598-64116; 65419-71585; 89295-120932
265	exon	GenCode	v33	exon	Y		N		11869-12227~12613-12721~13221-14409; 29534-29570~24738-24891~18268-18366~17915-18061~17606-17742~17233-17368~16858-17055~16607-16765~15796-15947~15005-15038~14404-14501; 17369-17436; 29554-30039~30564-30667~30976-31097; 30366-30503; 35721-36081~35277-35481~34554-35174; 52473-53312; 57598-57653~58700-58856~62916-64116; 65419-65433~65520-65573~69037-71585; 120775-120932~112700-112804~92091-92240~89295-91629
266	CDS	GenCode	v33	CDS	Y		N		65565-65573~69037-70008; 450740-451678; 685716-686654; 924432-924948~925922-926013~930155-930336~931039-931089~935772-935896~939040-939129~939275-939291; 959215-959240~958929-959081~957099-957273~956894-957025~956095-956215~955923-956013~954004-954082~953782-953892~953175-953288~952412-952600~952000-952139~951127-951238~948490-948603~948131-948232~946402-946545~946173-946286~945518-945653~945057-945146~944694-944800; 960694-960800~961293-961552~961629-961750~961826-962047~962355-962471~962704-962917~963109-963253~963337-963504~963920-964008~964107-964180~964349-964530~964963-965191; 966532-966614~966704-966803~970277-970423~970521-970601~970686-970758~970879-971006~971113-971208~971324-971404~972075-972150~972288-972424~972861-973010~973186-973326~973500-973640~973833-974051~974316-974364~974442-974575; 981137-981166~978881-980657~976499-976624~976172-976269; 999692-999973~999526-999613~999059-999432; 1014005-1014478
267	start_codon	GenCode	v33	start codon	Y		N		65565-65567; 451676-451678; 686652-686654; 924432-924434; 959238-959240; 960694-960696; 966532-966534; 981164-981166; 999971-999973; 1014005-1014007
268	stop_codon	GenCode	v33	stop codon	Y		N		70006-70008; 450740-450742; 685716-685718; 944694-944696; 965189-965191; 974573-974575; 976172-976174; 999059-999061; 1014476-1014478; 1054979-1054981
269	five_prime_UTR	GenCode	v33	5 prime UTR	Y		N		65419-65433~65520-65564; 451679-451697; 686655-686673; 923928-924431; 959241-959256; 960584-960693; 966482-966531; 982065-982093~981167-981173; 999974-1000172; 1001138-1001281~1008194-1008279~1013984-1014004
270	three_prime_UTR	GenCode	v33	3 prime UTR	Y		N		70009-71585; 450703-450739; 685679-685715; 944203-944693; 965192-965719; 974576-975865; 975204-976171; 998962-999058; 1014479-1014540; 1054982-1056116
271	transcript_length	GenCode	v33	transcript sequence length	Y		N		1657; 1351; 68; 712; 138; 1187; 840; 1414; 2618; 2748
272	transcript_sequence	GenCode	v33	transcript sequence	Y		N		GTTAACTTGCCGTCAGCCTTTTCTTTGACCTCTTCTTTCTGTTCATGTGTATTTGCTGTCTCTTAGCCCAGACTTCCCGTGTCCTTTCCACCGGGCCTTTGAGAGGTCACAGGGTCTTGATGCTGTGGTCTTCATCTGCAGGTGTCTGACTTCCAGCAACTGCTGGCCTGTGCCAGGGTGCAAGCTGAGCACTGGAGTGGAGTTTTCCTGTGGAGAGGAGCCATGCCTAGAGTGGGATGGGCCATTGTTCATCTTCTGGCCCCTGTTGTCTGCATGTAACTTAATACCACAACCAGGCATAGGGGAAAGATTGGAGGAAAGATGAGTGAGAGCATCAACTTCTCTCACAACCTAGGCCAGTGTGTGGTGATGCCAGGCATGCCCTTCCCCAGCATCAGGTCTCCAGAGCTGCAGAAGACGACGGCCGACTTGGATCACACTCTTGTGAGTGTCCCCAGTGTTGCAGAGGCAGGGCCATCAGGCACCAAAGGGATTCTGCCAGCATAGTGCTCCTGGACCAGTGATACACCCGGCACCCTGTCCTGGACACGCTGTTGGCCTGGATCTGAGCCCTGGTGGAGGTCAAAGCCACCTTTGGTTCTGCCATTGCTGCTGTGTGGAAGTTCACTCCTGCCTTTTCCTTTCCCTAGAGCCTCCACCACCCCGAGATCACATTTCTCACTGCCTTTTGTCTGCCCAGTTTCACCAGAAGTAGGCCTCTTCCTGACAGGCAGCTGCACCACTGCCTGGCGCTGTGCCCTTCCTTTGCTCTGCCCGCTGGAGACGGTGTTTGTCATGGGCCTGGTCTGCAGGGATCCTGCTACAAAGGTGAAACCCAGGAGAGTGTGGAGTCCAGAGTGTTGCCAGGACCCAGGCACAGGCATTAGTGCCCGTTGGAGAAAACAGGGGAATCCCGAAGAAATGGTGGGTCCTGGCCATCCGTGAGATCTTCCCAGGGCAGCTCCCCTCTGTGGAATCCAATCTGTCTTCCATCCTGCGTGGCCGAGGGCCAGGCTTCTCACTGGGCCTCTGCAGGAGGCTGCCATTTGTCCTGCCCACCTTCTTAGAAGCGAGACGGAGCAGACCCATCTGCTACTGCCCTTTCTATAATAACTAAAGTTAGCTGCCCTGGACTATTCACCCCCTAGTCTCAATTTAAGAAGATCCCCATGGCCACAGGGCCCCTGCCTGGGGGCTTGTCACCTCCCCCACCTTCTTCCTGAGTCATTCCTGCAGCCTTGCTCCCTAACCTGCCCCACAGCCTTGCCTGGATTTCTATCTCCCTGGCTTGGTGCCAGTTCCTCCAAGTCGATGGCACCTCCCTCCCTCTCAACCACTTGAGCAAACTCCAAGACATCTTCTACCCCAACACCAGCAATTGTGCCAAGGGCCATTAGGCTCTCAGCATGACTATTTTTAGAGACCCCGTGTCTGTCACTGAAACCTTTTTTGTGGGAGACTATTCCTCCCATCTGCAACAGCTGCCCCTGCTGACTGCCCTTCTCTCCTCCCTCTCATCCCAGAGAAACAGGTCAGCTGGGAGCTTCTGCCCCCACTGCCTAGGGACCAACAGGGGCAGGAGGCAGTCACTGACCCCGAGACGTTTGCATCCTGCACAGCTAGAGATCCTTTATTAAAAGCACACTGTTGGTTTCTG; ATGGGAGCCGTGTGCACGTCGGGAGCTCGGAGTGAGCGCACCATGACTCCTGTGAGGATGCAGCACTCCCTGGCAGGTCAGACCTATGCCGTGCCCTTCATCCAGCCAGACCTGCGGCGAGAGGAGGCCGTCCAGCAGATGGCGGATGCCCTGCAGTACCTGCAGAAGGTCTCTGGAGACATCTTCAGCAGGTAGAGCAGAGCCGGAGCCAGGTGCAGGCCATTGGAGAGAAGGTCTCCTTGGCCCAGGCCAAGATTGAGAAGATCAAGGGCAGCAAGAAGGCCATCAAGGTGTTCTCCAGTGCCAAGTACCCTGCTCCAGGGCGCCTGCAGGAATATGGCTCCATCTTCACGGGCGCCCAGGACCCTGGCCTGCAGAGACGCCCCCGCCACAGGATCCAGAGCAAGCACCGCCCCCTGGACGAGCGGGCCCTGCAGGAGAAGCTGAAGGACTTTCCTGTGTGCGTGAGCACCAAGCCGGAGCCCGAGGACGATGCAGAAGAGGGACTTGGGGGTCTTCCCAGCAACATCAGCTCTGTCAGCTCCTTGCTGCTCTTCAACACCACCGAGAACCTGTAGAAGAAGTATGTCTTCCTGGACCCCCTGGCTGGTGCTGTAACAAAGACCCATGTGATGCTGGGGGCAGAGACAGAGGAGAAGCTGTTTGATGCCCCCTTGTCCATCAGCAAGAGAGAGCAGCTGGAACAGCAGGTCCCAGAGAACTACTTCTATGTGCCAGACCTGGGCCAGGTGCCTGAGATTGATGTTCCATCCTACCTGCCTGACCTGCCCGGCATTGCCAACGACCTCATGTACATTGCCGACCTGGGCCCCGGCATTGCCCCCTCTGCCCCTGGCACCATTCCAGAACTGCCCACCTTCCACACTGAGGTAGCCGAGCCTCTCAAGACCTACAAGATGGGGTACTAACACCACCCCCACCGCCCCCACCACCACCCCCAGCTCCTGAGGTGCTGGCCAGTGCACCCCCACTCCCACCCTCAACCGCGGCCCCTGTAGGCCAAGGCGCCAGGCAGGACGACAGCAGCAGCAGCGCGTCTCCTTCAGTCCAGGGAGCTCCCAGGGAAGTGGTTGACCCCTCCGGTGGCTGGCCACTCTGCTAGAGTCCATCCGCCAAGCTGGGGGCATCGGCAAGGCCAAGCTGCGCAGCATGAAGGAGCGAAAGCTGGAGAAGCAGCAGCAGAAGGAGCAGGAGCAAGTGAGAGCCACGAGCCAAGGTGGGCACTTGATGTCGCTCCATGGGGGGACGGCTCCACCCAGCCTGCGCCACTGTGTTCTTAAGAGGCTTCCAGAGAAAACGGCACACCAATCAATAAAGAACTGAGCAGAAA; TGTGGGAGAGGAACATGGGCTCAGGACAGCGGGTGTCAGCTTGCCTGACCCCCATGTCGCCTCTGTAG; GTGCACACGGCTCCCATGCGTTGTCTTCCGAGCGTCAGGCCGCCCCTACCCGTGCTTTCTGCTCTGCAGACCCTCTTCCTAGACCTCCGTCCTTTGTCCCATCGCTGCCTTCCCCTCAAGCTCAGGGCCAAGCTGTCCGCCAACCTCGGCTCCTCCGGGCAGCCCTCGCCCGGGGTGCGCCCCGGGGCAGGACCCCCAGCCCACGCCCAGGGCCCGCCCCTGCCCTCCAGCCCTACGCCTTGACCCGCTTTCCTGCGTCTCTCAGCCTACCTGACCTTGTCTTTACCTCTGTGGGCAGCTCCCTTGTGATCTGCTTAGTTCCCACCCCCCTTTAAGAATTCAATAGAGAAGCCAGACGCAAAACTACAGATATCGTATGAGTCCAGTTTTGTGAAGTGCCTAGAATAGTCAAAATTCACAGAGACAGAAGCAGTGGTCGCCAGGAATGGGGAAGCAAGGCGGAGTTGGGCAGCTCGTGTTCAATGGTTTTGTCCGCCTTCCCTGCCTCCTCTTCTGGGGGAGTTAGATCGAGTTGTAACAAGAACATGCCACTGTCTCGCTGGCTGCAGCGTGTGGTCCCCTTACCAGAGTGAGGATGCGAAGAGAAGGTGGCTGTCTGCAAACCAGGAAGAGAGCCCTCACCGGGAACCCGTCCAGCTGCCACCTTGAACTTGGACTTCCAAGCCTCCAGAACTGTGAGGGATAAATGTAT; GGATGCCCAGCTAGTTTGAATTTTAGATAAACAACGAATAATTTCGTAGCATAAATATGTCCCAAGCTTAGTTTGGGACATACTTATGCTAAAAAACATTATTGGTTGTTTATCTGAGATTCAGAATTAAGCATTTTA; CACACAACGGGGTTTCGGGGCTGTGGACCCTGTGCCAGGAAAGGAAGGGCGCAGCTCCTGCAATGCGGAGCAGCCAGGGCAGTGGGCACCAGGCTTTAGCCTCCCTTTCTCACCCTACAGAGGGCAGGCCCTTCAGCTCCATTCTCCTCCAAGGCTGCAGAGGGGGCAGGAATTGGGGGTGACAGGAGAGCTGTAAGGTCTCCAGTGGGTCATTCTGGGCCCAGAGATGGGTGCTGAAGCTCCCACGCCTGCCTGTGAAAATGGAGTCCTCTCTCACCTGGGAGAGCCAGGTGCTGCCCCGAGAAGGATGCATTTATGGCTTCGTGAAGTCTTTCCTGACCCCCGATGCTGCTGACTATAGAGACAAAGTCTCACTATGTTGCTCAGGCTGGTCTTGAACTCCTGGCCTCAAGCGATCCTCCCACCTCAGCCTCCCAAAGTGTTGGGATTATAGACATGAGCCACTGCACCTGGCCGACCTTGGGCAAGTTCTTAAACCCTTCAAAGCCTCATTTTTCTCCAATCACAAAAGGGAAAGATGGTAATATTTTCCCCACCAAATTCTTGTCGGATGCCCTCACAGAATTGAGATTATGTACGTAAAACACCAGGTGCCTAACCCGGCACAGAGCAGGAGGGCTAAGCGTGACATCCAGCACGTGGTCAGTGGAATCCAGTATTCCTACCCACCTCTCTAGTCTCCCCTCCACCCCTCTCCCTTTCAGAGGCACCAAGCTGCTTGTGGTCTTGTCTATTCCCACTCCCTGCCTGACTGAACATTTTCTCCACCTCCTGATCATCAGCAGCAGAAACTGGCTGCTCTTCCTCCTGGGTAGACAGCCAGACTGTATTTCCCAGCTGCCCCTGCAGTGAGATGTGGCCATCGGAGCCAGCATTGGCCAATGGACTCTGCATGGGAGTGACGCATGCTGCCTCCAGGCTTGTCCCTAAAACCTCCCACGTGTCCTCCGCCTGCTCTTCCCACCTCCAAGGAGCACGGCAATTGTGGAAGACCCAGATTAGTGATGGCAGAACCATAGATGGGAGGAACCTGGGTCCCTGACTTAAAGTATCATGGATTTGGATGTTCCCTTAGTGAGAAATAAACTTCCATTGTGTTTAAGCCTTTATTTGTTTATAGTTGGTTACAGCAACTGCCTTCTTTTAATTAAAACACTCCTGCTGCT; GCGGTATCTAAATTTGTATTGATTGGACTTTCAAGCTCTTGGGAGATGCATCTTTTTCTTTTTTGGTTCTTCTCTGTGTTCTACATGGGAATTATCCTGGAAAATCTCTTCATTGTGTTCACAGTAATTATTGACTCTCATTTAAATTCCCCAGGTACTGCCTACTGGCCAACATTTATCTTCTTGATCTGGGTCTTCTCCTACAGTTCTGACTTTTTCACTAACTGCAGCATCATTTCTTTTCCAAGATGCATCATACAGATATTTTTCATTTGTGTCATGCGTAAAAATTGAGATGGTGCTGCTCATAACCATGGCATAGAGCAGGTACACTGCCAATCTGTAAGCCTCCCCATTACCTGACCACAATGAACCCCAAAATGTGTGTTTCCTTTGTTGGAGGCATCCTGGATAGTCAGGATAATCCATGCTGTATCTCAGTTTGTTTTTGCCATAAACTTGCCTTTTTGTGGCCCTAATAGAGTAGGTAGTTTTCACTGTGATTTTCCTTATGTCATGAAACTTGCTTGTGTAGACACTTACAAACTAGAGGTTGTAGTCACTGCTAACAGTGGGCTTATATCCATAGCTACCTGTTTCTTATTAATAATATCCTATATTTTCATTTCGGTAACCGTCTAGAATCCTTCTTCAGGAGACTTATCTAAAGCATTTGTGTCATGTTAGATCACATCACAGTAGGGATTTTGTTTTTTATGCCATGTATATTTCTGTATGTGTAGCCTTTGCCTAAAACAACACATGATTAATATTTGTTCATTGTTCCTTTTGCTATCACCCCTGTCTAGGATCTACACATTAAGAAACAAAGACATGAAC; AGCTATCTGAATTTCTCCTTCTCCTAAAAATGCACATCCTATGACTGAAAAGACAGGAAAGATGACAAACTCTATGGAAACTTGGCTTCTGAAGAACTCCTAGAAGCTTTCCAAAGTCATCAGTGTTTCCTAAGAAGGCAGAGAAATCAAACACATGGTCTTTTCCTCCAGACAAGCTCCTTTGGGTCATCAGGATTTCTTCAACAATAAAATGTTGCTTCAGAGTCTTCCCTTCTATCTGATTCAGTGGACCAAGTAAATGACTCTCTGGTAACAGAATTTGTATTACTTGGACTTGCACAATCCTTGGAAATGCAGTTTTTCCTTTTTCTCTTCTTCTCTTTATTCTATGTGGGAATTATCCTGGGAAAACTCTTCATTGTGTTCACAGTGATCTTTGATCCTCACTTACACTCCCCCATGTATATTCTGCTGGCCAACCTATCGCTCATTGACTTGAGCCTTTCATCTACCACAGTTCCTAGGTTGATCTACGATCTTTTTACTGATTGTAAAGTTATTTCCTTCCATAATTGCATGATACAAAAGTTCTTTATCCATGTTATGGGAGGAGTTGAAATGGTGCTGCTGATAGTCATGGCATATGATAGGTACACTGCGATCTGCAAGCCTCTCCACTATCCAACTATTATGAATCCCAAAATGTGCATGTTTTTGGTAGCAGCAGCTTGGGTCATTGGGGTGATTCATGCTATGTCTCAGTTTGTTTTTGTCATAAATTTACCCTTCTGTGGCCCTAATAATGTGGGGAGCTTTTATTGTGATTTTCCTCGGGTTATTAAACTTGCATGCATGGACACTTATGGGCTAGAATTTGTGGTCACTGCCAACAGTGGATTCATATCGATGGGCACCTTCTTTTTCTTAATTGTATCATACATTTTTATTCTGGTCACTGTCCAACGACATTCCTCAAATGATTTATCCAAAGCATTCTTCACTTCGTCGGCTCACATCACCGTAGTGGTTTTGTTTTTTGCTCCATGCATGTTTCTCTACGTGTGGCCTTTCCCTACTAAGTCATTGGATAAATTTTTTGCCATCATGAACTTTGTTGTCACCCCTGTCGTAAATCCTGCCATCTATACTTTAAGGAACAAAGATATGAAGTTTGCAATGAGAAGGCTGAATCAACATATTTTAAATTCTATGGAGACGACATAACACATTTGGTTGATGAGAGCACAGGATAAATGCCATGGACCATCAAGACTCCTGTGATCACCATGATCACTATGGAACGCGCACATTTTTAGTATTGCCTGAAAAAACTGAAAAATCTGCAAAAAGGATGCATTAAATCTAAGAATTGTATTTCAGATAAAGTTGCAACATTTTTTGTTAATCATAAAAAGTATATATTTCTATCTAATGTGTGTATCTAATTAACAGC; CCCAGATCTCTTCAGTTTTTATGCCTCATTCTGTGAAAATTGCTGTAGTCTCTTCCAGTTATGAAGAAGGTAACTGCAGAGGCTATTTCCTGGAATGAATCAACGAGTGAAACGAATAACTCTATGGTGACTGAATTCATTTTTCTGGGTCTCTCTGATTCTCAGGAACTCCAGACCTTCCTATTTATGTTGTTTTTTGTATTCTATGGAGGAATCGTGTTTGGAAACCTTCTTATTGTCATAACAGTGGTATCTGACTCCCACCTTCACTCTCCCATGTACTTCCTGCTAGCCAACCTCTCACTCATTGATCTGTCTCTGTCTTCAGTCACAGCCCCCAAGATGATTACTGACTTTTTCAGCCAGCGCAAAGTCATCTCTTTCAAGGGCTGCCTTGTTCAGATATTTCTCCTTCACTTCTTTGGTGGGAGTGAGATGGTGATCCTCATAGCCATGGGCTTTGACAGATATATAGCAATATGCAAGCCCCTACACTACACTACAATTATGTGTGGCAACGCATGTGTCGGCATTATGGCTGTCACATGGGGAATTGGCTTTCTCCATTCGGTGAGCCAGTTGGCGTTTGCCGTGCACTTACTCTTCTGTGGTCCCAATGAGGTCGATAGTTTTTATTGTGACCTTCCTAGGGTAATCAAACTTGCCTGTACAGATACCTACAGGCTAGATATTATGGTCATTGCTAACAGTGGTGTGCTCACTGTGTGTTCTTTTGTTCTTCTAATCATCTCATACACTATCATCCTAATGACCATCCAGCATCGCCCTTTAGATAAGTCGTCCAAAGCTCTGTCCACTTTGACTGCTCACATTACAGTAGTTCTTTTGTTCTTTGGACCATGTGTCTTTATTTATGCCTGGCCATTCCCCATCAAGTCATTAGATAAATTCCTTGCTGTATTTTATTCTGTGATCACCCCTCTCTTGAACCCAATTATATACACACTGAGGAACAAAGACATGAAGACGGCAATAAGACAGCTGAGAAAATGGGATGCACATTCTAGTGTAAAGTTTTAGATCTTATATAACTGTGAGATTAATCTCAGATAATGACACAAAATATAGTGAAGTTGGTAAGTTATTTAGTAAAGCTCATGAAAATTGTGCCCTCCATTCCCATATAATTTAGTAATTGTCTAGGAACTTCCACATACATTGCCTCAATTTATCTTTCAACAACTTGTGTGTTATATTTTGGAATACAGATACAAAGTTATTATGCTTTCAAAATATTCTTTTGCTAATTCTTAGAACAAAGAAAGGCATAAATATATTAGTATTTGTGTACACCTGTTCCTTCCTGTGTGACCCTAAGTTTAGTAGAAGAAAGGAGAGAAAATATAGCCTAGCTTATAAATTTAAAAAAAAATTTATTTGGTCCATTTTGTGAAAAACATAAAAAAAGAACTGTCACATCTTAATTTAAAAAATATATGCTTAGTGGTAAGGAGATATATGTCAACTTTTAAGAGGTTGAAAAACAAACGCCTCCCATTATAAGTTTATACTTCACCTCCCACCACTATAACAACCCAGAATCCATGAGGGCATTATCAGGAGTGAGTGGAAGAGTAAGTTTGCCAATGTGAAATGTGCCTTCTAGGTCCTAGACGTCTGTGGTATAACTGCTCATAAGCAGTAGAAAGAATTTAGAGGGATCCAGGCTCTCATCACGTTGGCACAAAGTATATTACTTGGATCCATCTATGTCATTTTCCATGGTTAATGTTTAAAAGCACAGGCTTTAAAGTAAAAAACAAAGAGCTGGATTCAACTCTACTGACTCTTATTAATCATGATTTTGGGCACATTACGTAGCTTTCATGAGCTTTAGTTTCTACATTTATAAACAGGAGATTATACCTATTATGCATGGTTATTATGAAGGAAAATGACAAAATAGATATAAATCAAATAGCCCACTTCGAGACATATTAAGCATGAATAAACATTAGATACTATTAAAATCCTATATATTAACAAAGCCAAAAGTTTCAAACTTTACTTTTTCCCAACATTCTTGTGAAATATGACACATCCCAATCTTAACAGATGCTCATTTGGGATACTGTACTTGTGAGTGGAAGTGTGTATATTTGTGTGCAAGTGTGTACTCATATACTTCCACCTTACCACCCTAGAAAGGCATGATGAAAATTTAAGATAGAAGGAAAATATAAATTGAAAAAAAAAAACCTTAACAAATGATTCTGACAAATATCTTCTCTTTCCAGGGAGAATCACTGAGCCAGAATAAAATTGAACACTAAATATTCTAAGAAAAAAGGAATCTAGTTTGTCAAAATGTGACTTGAATTAATAGATAAGGAGAGTCAGATGATAAGAGGGTCAAAATTATGTTTATCTTAGGAAAAGTAGAATAGAAAATTTATAAGCAGATTAAAAACACATAATAAAAGTAGTAAATAATAATGACAGTATCTCAAATCAGTGCAGGGGGGAAAGGCCTACTAATGTGATGGTGGGATAATTGGATAGCAATATGGGAAAAGATATATTTAATTTATTTGCTACACCAAATGCCAGGACAATCTCTAAGTGAATTCAAGACATAACTCTTTTTTCAAAAAAAC; CTGATCCATATGAATTCCTCTTATTAAGAAAAATAAAGCATCCAGGATTCAATGAAGAACTGACTATCACCTTGTTAATCATTCAGAAACATGTTGCAGGCTTAAGCCATTTTTGATATAGATACTGAAACAATTACTTGCTAAGAGCAAACTTGAAGTAACAATTTGGACAAGACAGCAAATGCTATTGTCCAAGTTTTCTAAAGAAGAATCTGAAGTGAAATGACATCAAGAGACCTATCAAGACCTGTATCCAGGAAAAGACCAAACCAATGCAGACCAAACCAATGCAGAACTCCTATGTGCTGATGGTGGTCTTACATTTCCCTAAGTTTCTGCCGACTAAACTGTGCACACGTTCTCAGGACCTCCTGAAGCTGCGTCACAGGCACTAATCAAAGAACACAACCAAGAGTTTGGCCTTTTCTTCAGCACTGGGAATTGTGATCCAAAGCTTTTCCCGATGAAGCACAAAGTTGGAGAAAAAAAAACGCAAACTAAACAACCACAATGAAACAGAACAGAGTTAATCTGCTGTAGCTCAAGAGAGGATGTACCTGCCCCCACCCCGCATCCCTGGGCTCGGGTTTGCCTTGCTGACCTCTGCTGCCACCTGGTGCCACACAGAGAAACTGAGGAGAAACCACATCAGTCTCCTTCAGCCTCAGCTTCACATCTGTGGGTCAAGCAACCCTTTCAGAAGCTGTATAATGTGGGAAAGCTTTCCTCTCAGGAAAATGCACACATCCAACTTTGAGAAGATGCCCTTGGGGGCGCTTCAAGGATTCTAGATAATAACCCCCTTTCCCGAACATCCAAGAACCTAAGATTTTTTTTTTTTTGAGAAAGTCTCGCTCTCTCTCCCAGTCTGGAGTGCAGTGGCGTGATCTTGGCTCACTGCCAGCTCCACCTCCCAGGTTCACGCCATTCTCCTGCTTCAGCCTCCCAAGTAGCTGGGGCTACAGGCACCTGCCACCAAACCCGGCTAATTTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCAGGATCGTCTTGATCTCCTGACCTTGTGATCCACCCGCCTCGGCCTCCCAAATTGCTGGGATTACAGATGTGAGCCACCGCACCTGGTCCAAGAACCCAAGTTTTAGATCTAGAGTGATGTCAGCATGACATTGATTTCCTGAGGCCCAGGGGCGAAGGAGCTGAGGACAGCAGAGGGGTGAAGGAACTCAGCTACAGACAGCAGCAGCTGATGCACAGGCCTCCCAGCGCCTGAAGTCACCCGGAATTGGGAAGTGCTCAGAAGCTTACAAAGCTGCCTCGAGGTGGGAACATGACATAAATCCAAGAGCAGATCCCTGATCCTATAAAAATGTACTAGATGCAGTGGGGGCATTTTAAATGAGCAGAGAAGGACAGACAGATAAACAGAAGGACAAACAGTATTGGGATTGGGATAAATGCTCAGCTTTTGCCCAAATCTTAGTGACTTAAGCATCACTTATTTGCTCACGATTCTGTGGCTGGACCATTTGGTTTGGCTCACAGGGCAGGGACTGTGCTGGTCTTACCTGAGCAGACCTGCATGTCTGCGGTCAACTGGGTTGGCAGAGACAGAGTGACTGTCTTCCTCCAGGAAGCAGCAGGTTAACTGGTTGGCAGAGACAGAGGGACAGAGGGACTGTCTTCCTCCAGGAAGCAGCAGGTTAACTGGTTGGCAGAGACAGAGGGACAGAGGGACTGTCTTCCTCCAGGAAGCAGCAGGTTAACTGGTTGGCAGAGACAGAGGGACTGAGGGACTGTCTTCCTCCATGAAGCAGCAGGTTAACTGGTTGGCAGAGACAGAGGGACTGAGGGACTGTCTTCCTCCAGGAAGCAGCAGGTTAACTGGTTGGCAGAGACAGAGGGACTGAGGGACTGTCTTCCTCCAGGAAGCAGCAGGTTAACTGATTGGCAGAGACAGAGGGACTGAGGGACTGTCTCCCCCCAGGAAGCAGCAGGTTGGCTCTGTTTCCTTCGTGGGGCAGCTGGTCTCCAGGGCAGCAAGAGAGACCAAGCCCCAGTGCACATTCTACAGCCTCTGTGCACATCAGACTTGTTAATATCCCATTGGCCAGTGTAAGTCACTTGGCCAAGCCCAGATTAAGGAGTGGAAAGATGGAGGCTATCTCCTCCTGGGAGAGGAGGCAAAGGAGGTGGGAGTATTATGTGGCCACTTATGTTTGCAATCTACCATACTTAGCACTTTGAGAAAAGAATTAACTGAGAAACTTGCTTCAAATAGGGCCAGTAAAATGAAGCCCCAATTGAAGTAAAATGCATATATAAAAAATGAAACTGTGACCGATTTTAAGGACAGTATTGGCAAATATTTCTGTGCTCTTGGAGGAGAAGACCCTTATTGGCATGACATGTCAGAAACCACAATGAAAGAATTATTTTAACTTGCATTCATAAAAATTAAAATTATTCATTAAAAACATCGTGAATGAAATTAAAAGTCAAAATGTAAGCCAGAAAATTATTTACAACGTATGTGTCAGGAAAAGACAATACCCTTCAAACTTTGAGAGTTTACATCAGAAAGAAAACAGCAAATGACATGATCCAAACTTGATAAAGGACATGAAAAAGAGCCAGCACTTAGTATGTTTTCTGAATGAATAAGTAGCCAACAGCACATGAAAATGCGTGTAATCCATTTGTAAGCAGAGAAATGCAAACTAAAACAGTAAAGTGTCATTTTCACTTCCTGG
273	protein_length	GenCode	v33	protein sequence length	Y		N		0; 326; 312; 358; 749; 642; 611; 676; 247; 157
274	protein_sequence	GenCode	v33	protein sequence	Y		N		,ENST00000450305.2; ,ENST00000469289.1; ,ENST00000461467.1; ,ENST00000492842.2; MKKVTAEAISWNESTSETNNSMVTEFIFLGLSDSQELQTFLFMLFFVFYGGIVFGNLLIVITVVSDSHLHSPMYFLLANLSLIDLSLSSVTAPKMITDFFSQRKVISFKGCLVQIFLLHFFGGSEMVILIAMGFDRYIAICKPLHYTTIMCGNACVGIMAVTWGIGFLHSVSQLAFAVHLLFCGPNEVDSFYCDLPRVIKLACTDTYRLDIMVIANSGVLTVCSFVLLIISYTIILMTIQHRPLDKSSKALSTLTAHITVVLLFFGPCVFIYAWPFPIKSLDKFLAVFYSVITPLLNPIIYTLRNKDMKTAIRQLRKWDAHSSVKF,ENST00000335137.4; ,ENST00000477740.5; ,ENST00000490997.5; ,ENST00000448958.2; ,ENST00000412666.1; ,ENST00000453935.1
